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The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision.
The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth
surface being essential for its optical properties. Disorders of the corneal epithelium include superﬁcial
punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of
these disorders is important for minimization of further damage to the cornea. Currently available
treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in
order to allow natural healing to proceed. PEDs remain among the most difﬁcult corneal conditions to
treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular
biological levels, we have strived to develop new modes of treatment for these defects. These treatments
rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein ﬁbronectin, for the
attachment and migration of corneal epithelial cells, and activation of these cells by biological agents
such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both ap-
proaches is the role of the ﬁbronectineintegrin system in corneal epithelial wound healing. Determi-
nation of the minimum amino acid sequences required for the promotion of corneal epithelial wound
closure by ﬁbronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the
development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent
molecules.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Both the structure and function of the cornea are rather simple
compared with those of other tissues and organs. The cornea
nevertheless plays a key role in vision as a result of its transparency
and refractive power. It is thus necessary for the cornea to be clear
and transparent for it to allow external light to enter through the
pupil and lens and to reach the retina. The smooth surface of the
cornea and its stable shape with appropriate refractive power are
also essential for the focusing of external light and formation of
clear images on the retina.
The human cornea contains a stratiﬁed epithelium at its
external surface with a thickness of ~50 mm, which accounts for
~10% of the total thickness of the cornea. This epithelium comprises
ﬁve or six layers of epithelial cells, including basal cells, wing cells,
and superﬁcial cells. Only basal cells have mitogenic activity, and
they differentiate consecutively into wing cells and superﬁcial cells.
The superﬁcial cells undergo desquamation as a result either of the
mechanical friction associated with blinking (Lemp and Mathers,
1989; Mathers and Lemp, 1992; Pﬁster, 1973) or of apoptosis
(Glaso et al., 1993; Kinoshita et al., 2001; Ren and Wilson, 1996,
1997; Wilson et al., 1996). The mechanisms of cell-to-cell and
cell-to-matrix interaction differ among the cell layers of the
epithelium. Integrins, which serve as receptors for extracellular
matrix (ECM) proteins, are expressed predominantly in the basal
epithelial cells and mediate the tight adherence of these cells to the
basement membrane. Gap junctions composed of connexin 43 are
present only in basal cells and subserve intercellular communica-
tion between these cells. On the other hand, tight junctions, con-
sisting of proteins such as zonula occludens (ZO)-1 and occludin,
are present mainly in the superﬁcial cells and confer barrier
properties on the entire epithelium. A well-layered structure and
orderly differentiation process are essential for the maintenance of
corneal transparency and clarity (Nishida and Saika, 2011; Suzuki
et al., 2003).
The body has acquired passive protective and active repair
mechanisms through the process of evolution in order to surviveenvironmental insults. These mechanisms maintain the normal
structure and function of the body as well as repair injured com-
ponents to restore their structure and function. Epithelia form the
boundary of the body with the external environment, covering its
entire surface and protecting the internal milieu from outside in-
sults. Damage to or disorders of epithelia often result in inﬂam-
mation or the activation of ﬁbroblasts and other cell types that are
normally isolated from the external environment. Epithelial wound
healing is thus an important biological process for restoration of the
normal structure and function of tissues and organs subjected to
mechanical, chemical, or biological insults. Otherwise, a loss of or
break in tissue continuity would persist and tissue dysfunction
would proceed.
The ocular surface is covered by the corneal and conjunctival
epithelia, with the transition between these two epithelia being
located at the limbus. Stem cells for the corneal epithelium are
located at the limbus (Dua and Azuara-Blanco, 2000; Osei-
Bempong et al., 2013; O'Sullivan and Clynes, 2007; Yoon et al.,
2014).
The conjunctival epithelium is folded to form the bulbar con-
junctiva and palpebral conjunctiva. The anatomic characteristics of
the corneal and conjunctival epithelia are distinct (Fukuda and
Nishida, 2010b; Kinoshita et al., 2001). Whereas both face the
external environment, the corneal epithelium forms a tight barrier
but the conjunctival epithelium does not. The cornea is also an
avascular tissue, whereas the conjunctiva has an extensive vascular
system. Furthermore, immune cells, such as mast cells, lympho-
cytes, and eosinophils, are abundant in the conjunctiva, but they are
present in only low numbers in the cornea (Allansmith et al., 1978;
Morgan et al., 1991). In addition, mucin-secreting (goblet) cells are
present only in the conjunctival epithelium (Argueso and Gipson,
2001; Gipson, 2004). Given that the conjunctival and corneal
epithelia are separated by tear ﬂuid (Gipson, 2007), inﬂammatory
reactions in the conjunctiva can spread to the cornea through tear
ﬂuid and vice verse (Nishida, 2010a).
Tear ﬂuid is an evolutionary adaptation to life on dry land that
arose to prevent desiccation of the ocular surface. In addition, tear
Table 1
Corneal epithelial disorders.
Disorder Affected epithelial
layers
Basement membrane
involvement
Causative
pathology
Superﬁcial
punctate
keratopathy
(SPK)
Superﬁcial
epithelial cells only
Intact basement
membrane or anterior
basement membrane
dystrophy
Dry eye
Foreign body
Toxic
keratopathy
Diabetes
Erosion Simple
erosion
Defect of entire
thickness of
epithelium.
Intact remaining
epithelium
Intact basement
membrane
Trauma
Contact lens
overwearing
Recurrent
erosion
Defect of entire
thickness of
epithelium.
Intact remaining
epithelium
Anterior basement
membrane dystrophy
Trauma with
shearing
forces
Prior
infection
Persistent
epithelial
defects (PEDs)
Defect of entire
thickness of
epithelium.
Weak epithelial
adhesion and
edema at the defect
margin
No basement
membrane.
Melting of shallow
stroma
Neurotrophic
keratopathy
Diabetic
keratopathy
Prior
infection
Infectious
ulcer
Immunologic
ulcer
Chemical or
thermal
injury
Stem cell
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kines and chemokines (Nishida, 2006). Dry eye is a multifactorial
disease of tear ﬂuid and the ocular surface that is characterized by
symptoms of ocular discomfort, visual disturbance, and tear ﬁlm
instability and can result in damage to the ocular surface (Lemp
et al., 2007). The condition of tear ﬂuid affects that of the corneal
epithelium. Conversely, the condition of the cornea and conjunctiva
inﬂuences the quality of tear ﬂuid. The corneaetear ﬂuid-
econjunctiva axis thus plays a key role in inﬂammatory reactions at
the ocular surface and in ocular surface disturbances.
Although the surface of the cornea is continually exposed to
environmental threats as a result of its anatomic location, the
corneal epithelium is equipped with active repair mechanisms. In
the case of most corneal epithelial injuries, the defects are resur-
faced rapidly by the remaining epithelial cells at a rate of about
1 mm2/h (Hanna et al., 1961) and without serious aftereffects.
Under certain conditions, however, the cornea develops various
types of epithelial disorders, such as superﬁcial punctate keratop-
athy, corneal erosion, and persistent corneal epithelial defects (also
known as nonhealing epithelial defects). These disorders may arise
as a result of changes either in the activities of epithelial cells or in
conditions such as the shape of the lid margin, inﬂammation at the
ocular surface, the amount or quality of tear ﬂuid, or nerve activity.
Furthermore, in the presence of systemic disease or a deteriorating
local environment, complete repair of corneal epithelial damage is
not achieved and more serious conditions can develop.
Limbal stem cells serve as a reservoir for corneal epithelial cells,
so that depletion or loss of function of these stem cells can result in
a lack or deﬁciency of healthy (terminally differentiated) cornealFig. 1. Classiﬁcation of corneal epithelial disorders. Schematic representations, pho-
tographs, ﬂuorescein staining (erosion and PEDs), and laser confocal biomicroscopy
(SPK) of affected eyes are shown.
deﬁciencyepithelial cells and in the consequent development of persistent
epithelial defects (Mort et al., 2012; Notara et al., 2010; Osei-
Bempong et al., 2013; Secker and Daniels, 2008; Yoon et al., 2014)
Thymosin b4 is a small protein of 43 amino acids (Low et al., 1981)
that stimulates hair growth and corneal epithelial wound healing
through promotion of stem cell migration, inhibition of corneal
epithelial cell apoptosis, and an anti-inﬂammatory action (Philp
et al., 2007; Sosne et al., 2001, 2002, 2004, 2006, 2007a,b). Clini-
cally, thymosin b4 has been found to be effective for the treatment
of neurotrophic keratopathy and dry eye syndrome (Dunn et al.,
2010; Sosne et al., 2012).
Unfortunately, few drugs are available to treat corneal epithelial
disorders based on the pathobiology of the symptoms. Available
treatments include artiﬁcial tears of various osmolarities, hyalur-
onan eyedrops, oily ointments, steroids, nonsteroidal anti-
inﬂammatory drugs (NSAIDs), and immunosuppressive agents.
None of these treatments target the activity of corneal epithelial
cells, however. Rather, they protect the corneal surface either
directly or by attenuation of inﬂammation, thereby improving the
local environment or circumstances in order to support the natural
healing process. In addition, patients with ocular surface infections
can be treated with antibiotics or other antibacterial, antiviral, or
antifungal agents. Although the number of individuals with non-
healing epithelial defects of the cornea is relatively small, there is
an unmet need for drugs that target corneal epithelial cells in order
to facilitate epithelial wound healing and to restore the smooth
surface of the cornea.
Over the last several decades, many studies have investigated
factors that might accelerate the wound healing process in the
corneal epithelium (Imanishi et al., 2000; Nishida and Tanaka,
1996; Schultz et al., 1992; Wilson et al., 2001). These factors have
included epidermal growth factor (EGF) (Daniele et al., 1979; Ho
and Elliott, 1975; Nishida et al., 1990; Schultz et al., 1988; Soong
T. Nishida et al. / Progress in Retinal and Eye Research 47 (2015) 38e63 41et al., 1989; Watanabe et al., 1987, 1988; Yu et al., 2010) as well as
various other growth factors such as ﬁbroblast growth factor (FGF),
hepatocyte growth factor, keratinocyte growth factor, and nerve
growth factor (Gospodarowicz et al., 1977; Grant et al., 1992;
Lambiase et al., 2000, 2012; Sotozono et al., 1994; Wilson et al.,
1993). In addition, extracellular matrix components such as ﬁbro-
nectin have been shown to facilitate corneal epithelial wound
healing (Nishida, 2010b, 2012). A major drawback of many of these
biologically active agents has been the induction of unwanted ef-
fects on various components of the anterior segment of the eye,
such as the induction of corneal neovascularization by EGF. It is
thus important to identify factors that promote corneal epithelial
wound healing without adverse effects, or to modify agents so that
they retain beneﬁcial effects but lack undesirable effects of the
parent molecule.
In this review, wewill address new drug development strategies
for the treatment of ocular surface disturbances, with emphasis on
persistent epithelial defects of the cornea. We will present possible
targets for such drugs and as well as our scientiﬁc and clinical
ﬁndings with ﬁbronectin and the combination of substance P and
insulin-like growth factor-1 (IGF-1).
2. Targets for new drug development for corneal epithelial
pathologies
Whenever a patient is encountered whose corneal epithelial
disorder cannot be cured by currently available prescription drugs
or surgery, the need for the development of new treatments is
apparent. To clarify the targets for new drug development, we ﬁrst
need to consider the various types of corneal epithelial disorder
and their origins. Corneal epithelial disorders can generally be
classiﬁed into three categories based on pathophysiology: super-
ﬁcial punctate keratopathy, corneal erosion, and persistent corneal
epithelial defects (Fig. 1, Table 1).
2.1. Superﬁcial punctate keratopathy
Superﬁcial punctate keratopathy (SPK) affects only the superﬁ-
cial layer of the corneal epithelium, and it is identiﬁed by punctate
ﬂuorescein staining at the corneal surface. Laser confocal bio-
microscopy reveals the presence of dispersed defects encompass-
ing individual or a few superﬁcial epithelial cells (Zhivov et al.,
2006), with the punctate staining apparent with ﬂuorescein cor-
responding to each cellular defect (Mokhtarzadeh et al., 2011). SPK
is thought to result from a loss of balance between the differenti-
ation and apoptosis of basal, wing, and superﬁcial epithelial cells,
and it may be triggered by factors in the environment surrounding
the cornea. The corneal epithelium forms a secure barrier to water,
ions, and various deleterious agents (Klyce and Crosson, 1985;
Mishima and Hedbys, 1967). This barrier function of the corneal
epithelium is conferred as a result of the formation of intercellular
tight junctions containing ZO-1 between superﬁcial epithelial cells.
The permeability of the corneal epithelium is measured clinically
by ﬂuorophotometry (Kinoshita et al., 2001) and is increased with
age, in individuals with diabetes mellitus or dry eye syndrome, as
well as prior to the onset of SPK (Chang and Hu, 1993; Gobbels and
Spitznas, 1992; Gobbels et al., 1989; Klyce et al., 1985; Yokoi and
Kinoshita, 1995). SPK is one of the signs of dry eye (Amano et al.,
2006; Kaido et al., 2011; Miyata et al., 2003), and a low level of
tear secretion, an excess of cytokines in tear ﬂuid, or exposure to
toxic materials such as the preservatives in prescription eyedrops
may induce the punctate loss of superﬁcial epithelial cells (DeRosa,
1998). Furthermore, a pathological condition affecting the base-
ment membrane, such as anterior basement membrane dystrophy
or diabetic keratopathy, may inﬂuence the differentiation of cornealepithelial cells and result in the development of SPK (Schultz et al.,
1981; Wakuta et al., 2007).
The choice of drugs for the treatment of SPK depends on its
etiology. In the case of low tear secretion, the administration of
artiﬁcial tear ﬂuid or viscous hyaluronan eyedrops is preferred.
Steroid or NSAID eyedrops should be administered in the presence
of conjunctival inﬂammation or meibomian gland dysfunction.
Overnight coverage of the corneal surface with oily ointment is also
effective in some cases. Two new drugs, diquafosol and rebamipide,
have recently been approved in Japan for the treatment of dry eye
syndrome. Diquafosol is a P2Y2 purinergic receptor agonist that
stimulates the release of water by conjunctival epithelial cells (Lau
et al., 2014; Murakami et al., 2004; Shaver, 2001; Shimazaki-Den
et al., 2013). It also possesses scavenging activity for free radicals
and stimulates cyclooxygenase-2 activity and consequent prosta-
glandin production. Clinical studies performed in Japan have shown
that diquafosol is effective in reducing the extent of punctate
ﬂuorescein staining of the corneal epithelium, a major objective
sign of dry eye syndrome (Koh et al., 2013; Matsumoto et al., 2012;
Nakamura et al., 2012; Nichols et al., 2004; Takamura et al., 2012).
Rebamipide has anti-inﬂammatory actions in the gastrointestinal
tract (Genta, 2003; Haruma and Ito, 2003) and has long been pre-
scribed as an oral drug for the treatment of gastritis (Arakawa et al.,
2005, 1995). It also exerts anti-inﬂammatory actions at the ocular
surface. It thus increases the secretion of mucin-like substances by
corneal epithelial cells (Takeji et al., 2012; Urashima et al., 2012),
suppresses cytokine production by corneal epithelial cells (Fukuda
et al., 2014) and conjunctival epithelial cells (Tanaka et al., 2013;
Ueta et al., 2013), up-regulates barrier function of the corneal
epithelium (Kimura et al., 2013; Tanaka et al., 2013), and thereby
reduces epithelial punctate keratopathy in the rabbit cornea and
conjunctiva (Urashima et al., 2004). In the clinical setting, the
administration of rebamipide ophthalmic suspension ameliorates
SPK associated with dry eye syndrome (Itakura et al., 2013;
Kashima et al., 2012, 2014; Kinoshita et al., 2014, 2013).
SPK is thus a major sign of dry eye syndrome and is caused by
various different factors (Lemp et al., 2007). Although several local
treatmentsdsuch as artiﬁcial tears, hyaluronan eyedrops, diqua-
fosol eyedrops, and rebamipide suspensiondimprove the micro-
environment of the corneal surface and thereby ameliorate SPK and
dry eye, new drugs that target the function of corneal epithelial
cells would be expected to provide a better option for such
treatment.
2.2. Corneal erosion
Corneal erosion is characterized by loss of the entire thickness of
the corneal epithelium. There are two types of corneal erosion:
simple and recurrent. Simple erosion is usually the result of injury
to the corneal surface and is apparent as a sharply deﬁned region of
ﬂuorescein staining. This staining reveals that the remaining
epithelial cells are ﬁrmly attached to the underlying basement
membrane. The remaining epithelial cells begin to migrate over the
area of the defect immediately after the injury, resulting in rela-
tively rapid coverage of the injury site in most cases. Active treat-
ment is not required for this type of injury in the absence of
underlying conditions, such as infection or diabetes, that might
delay or block epithelial wound healing. Prophylactic administra-
tion of antibacterial agents may be recommended.
Recurrent erosion is caused by shearing forces acting at the
corneal surface, such as those that might result from a nail injury,
and it is associated with anterior basement membrane dystrophy,
such as lattice corneal dystrophy. Some individuals with diabetes
show a tendency to develop recurrent erosion. Retro-illumination
reveals the presence of small transparent deposits under the
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The healing pattern for each episode of recurrent erosion is similar
to that for simple erosion. Current treatments are identical to those
for simple erosion, although ﬁne needle puncture has been found to
be effective for prevention of recurrence (Watson and Barker, 2007;
Watson et al., 2012). Adhesion of the epithelium is weak in cases of
recurrent erosion, however, and mild debridement is readily ach-
ieved with a ﬁne cotton swab. We have treated such patients by
epithelial debridement followed by removal of the underlying de-
posits by washing. There is a need for new treatments that would
accelerate epithelial wound healing by stimulating epithelial cell
migration and adhesion to the underlying matrix (Morita et al.,
2012).
2.3. Persistent corneal epithelial defects (nonhealing epithelial
defects)
Persistent epithelial defects (PEDs) of the cornea occur when the
total thickness of the epithelium is lost and there is no sign of the
initiation of epithelial resurfacing by remaining epithelial cells or
intact stem cells of the epithelium at the limbus. Clinically, this
condition is characterized by ﬂuorescein staining of the defect area
and ground glass-like opacity surrounding the defect area. The
margin of the defect area shows weak adhesion of the remaining
epithelium to the underlying basement membrane or stroma. The
principal difference between simple corneal erosion and PEDs, both
of which show a loss of all epithelial layers, is the condition of the
epithelium in the marginal area. The epithelium in the marginal
area adheres ﬁrmly to the underlying matrix in simple corneal
erosion, with the result that ﬂuorescein dye does not seep under
the remaining epithelium. In contrast, in the case of PEDs, seeping
of ﬂuorescein under the marginal epithelium renders the margin
indistinct and fuzzy. Indeed, it is possible to predict whether
epithelial resurfacing will take a long time or perhaps never begin
on the basis of the condition of the epithelium at the margin of the
defect area.
PEDs developmost commonly in patients with dry eye, inwhom
the quantity or quality of tear ﬂuid is diminished, and in those with
reduced corneal sensation as a result of nerve damage or degen-
eration. The lack of stimulation of corneal epithelial cells by growth
factors and cytokines in tear ﬂuid or by neuropeptides released
from the trigeminal nerve results in failure of the corneal epithe-
lium to maintain a normal structure and to initiate a healing
response. These pathological backgrounds can lead to the devel-
opment of various types of corneal epithelial disturbance (Lemp
et al., 2007; Smith et al., 2007), the most severe of which are
PEDs associated with dry eye syndrome. Dysfunction of the tri-
geminal nerve may lead to serious corneal epithelial disturbances
referred to as neurotrophic keratopathy. Possible causes of neuro-
trophic keratopathy include systemic diseases such as diabetes
mellitus and certain genetic disorders, central nervous system ab-
normalities such as brain tumors and complications of neurosur-
gery, and various insults to the ocular surface such as herpes
simplex virus infection, penetrating keratoplasty or LASIK surgery,
abuse of topical anesthetics, and toxicity of ophthalmic drugs
(Lambiase et al., 1999; Nishida, 2005; Nishida and Yanai, 2009).
Clinical regeneration of trigeminal nerve ﬁbers is not currently
possible, and management of neurotrophic keratopathy remains
difﬁcult (Bonini et al., 2003; Goins, 2005; Nishida, 2010b; Okada
et al., 2010; Pushker et al., 2001; Reynolds and Kabat, 2006).
PEDs are also associated with shield ulcer in individuals with
vernal or atopic keratoconjunctivitis (Cameron, 1995; Kumagai
et al., 2006; Kumar, 2009). In this instance, the underlying pa-
thology may differ from that of PEDs associated with dry eye or
neurotrophic keratopathy. Severe allergic reactions in the palpebralconjunctiva result in the release of histamine, leukotrienes
(Garceau and Ford-Hutchinson, 1987), proteinases (Kumagai et al.,
2002), as well as eosinophil-derived cytotoxic proteins such as
major basic protein, eosinophil cationic protein, eosinophil perox-
idase, and eosinophil-derived neurotoxin (Trocme et al., 1989).
Eosinophil-derived cytotoxic proteins in particular can damage
corneal epithelial cells and retard corneal epithelial wound healing
(Fukuda and Nishida, 2010a,b; Trocme et al., 1989). The develop-
ment of giant papillae in vernal keratoconjunctivitis induces me-
chanical stress that also results in delayed corneal epithelial
resurfacing. Furthermore, the deposition of ﬁbrin and mucous
cellular debris at the site of epithelial defects results in the for-
mation of plaque that prevents the attachment and migration of
corneal epithelial cells and thereby leads to persistence of epithelial
defects. Treatment of PEDs in such patients includes suppression of
allergic reactions, removal of mechanical stimuli in the form of
giant papillae, removal of plaque, and facilitation of corneal
epithelial resurfacing (Fukuda et al., 2010; Guo et al., 2013; Kumagai
et al., 2005; Reddy et al., 2013).
Chemical or thermal burns of the cornea and Stevens-Johnson
syndrome are associated with stem cell deﬁciency at the limbus
and a consequent insufﬁcient supply of corneal epithelial cells for
epithelial resurfacing and the persistence of epithelial defects.
Although the signs of PEDs appear to be identical regardless of
whether limbal stem cells are intact or not, it is important to
differentiate PEDs with intact stem cells from those caused by stem
cell deﬁciency.
There are no speciﬁc and curative treatment modalities for PEDs
of the cornea. Whereas the development of drugs that target
directly the function of corneal epithelial cells and thereby
ameliorate corneal epithelial disturbances is desirable, most
currently available ophthalmic drugs serve to improve the envi-
ronment at the ocular surface. Only symptomatic treatments have
been applied, with the expectation that natural epithelial resur-
facing may occur. Forced eye patches, therapeutic soft contact
lenses (Blackmore, 2010; Choi and Chung, 2011; Schrader et al.,
2006), oily ointments, tarsorrhaphy (Baum, 1987; Cosar et al.,
2001; Panda et al., 1999), and amniotic membrane trans-
plantation (Brijacak et al., 2008; Gris et al., 2002; Lee and Tseng,
1997; Panda et al., 1999; Turkoglu et al., 2014) have thus been
applied to protect the corneal surface from external insults. In
addition, administration of artiﬁcial tears, viscoelastic (such as
hyaluronan or chondroitin sulfate) eyedrops, punctal plugs (Tai
et al., 2002), and ﬁbrin glue (Sumich et al., 2003) as well as
improved lid hygiene have been tried. Autologous serum eyedrops
(Geerling et al., 2004; Matsumoto et al., 2004; Mukerji et al., 2002;
Noble et al., 2004), umbilical cord serum (Vajpayee et al., 2003;
Yoon et al., 2005, 2007), EGF (Daniele et al., 1992), and plasma
rich in growth factors (Cho et al., 2013; Geerling et al., 2004; Kim
et al., 2012; Lopez-Plandolit et al., 2010; Mukerji et al., 2002;
Poon et al., 2001; Tsubota et al., 1999b; Vajpayee et al., 2003) have
also been examined in the clinical setting, but none of these
treatment modalities has been conﬁrmed to be effective scientiﬁ-
cally (Pan et al., 2013).2.4. Concepts for new drug development for PEDs
Cavanagh and colleagues stated in 1976 that “The endogenous
biochemical control mechanisms which regulate epithelial cell
movement, mitosis, and the synthesis of basal lamina must be
understood ﬁrst in order to interpret correctly any pathologic
alteration” (Cavanagh et al., 1976). Even today, almost 4 decades
later, this contention is still relevant. Progress in cell and molecular
biology has provided insight into epithelial wound healing and the
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matrix (ECM) proteins in this process.
Epithelial resurfacing is regulated by many biologically active
agents including growth factors, cytokines, and chemokines (Lim
et al., 2003; Suzuki et al., 2003; Werner and Grose, 2003).
Furthermore, the condition of the basement membrane on which
epithelial cells migrate is another important determinant of this
process. The degradation of basement membrane components is
mediated in part by plasmin and urokinase-type plasminogen
activator (u-PA), the latter of which is secreted from injured corneal
epithelial cells as well as from activated keratocytes in the corneal
stroma (Morimoto et al., 1993). Excessive degradation of the
basement membrane prevents the adherence of epithelial cells and
their subsequent migration (Berman et al., 1983). Plasminogen
activator activity is increased in the tear ﬂuid of individuals with
PEDs (Berta et al., 1990).
Adhesion of epithelial cells to underlying ECM through the
interaction of cellular integrins with ﬁbronectin is required in the
early stages of active cell locomotion. Detachment of cells from the
matrix is also required, however, for the active movement or
migration of these cells, and this detachment is mediated in part by
degradation of matrix proteins. The addition of either immuno-
globulin G speciﬁc for human u-PA or protease inhibitors was thus
shown to retard migration of the rabbit corneal epithelium ex vivo,
indicating that u-PA activity is essential for this process (Morimoto
et al., 1993). Immunostaining and in situ zymography of the
wounded rabbit cornea have also revealed that u-PA expression
and activity are restricted to the leading edge of the migrating
epithelium at the wound margin (Watanabe et al., 2003). Annexin
A5, a Ca2þ-dependent phospholipid-binding protein, up-regulates
u-PA release from corneal epithelial cells and was found to pro-
mote corneal epithelial wound healing both in vitro and in vivo
(Watanabe et al., 2006). The migration of corneal epithelial cells
thus requires not only cell attachment to ﬁbronectin in the ECM but
also cellular detachment that is mediated by the degradation of
ﬁbronectin and triggered by the release of cellular u-PA.
Given that corneal epithelial adhesion and migration are regu-
lated by biological factors present in tear ﬂuid, the pathology of
PEDs depends largely on the amount of tear ﬂuid and the amounts
and types of biologically active agents therein (Barabino et al., 2012;
Kinoshita et al., 2001; Lim et al., 2003; Nishida, 2006; Pﬂugfelder,
2011). It is also inﬂuenced by the presence of melting of stromal
collagen (corneal ulceration) and of systemic diseases such as
diabetes. In addition, PEDs are associated with low corneal sensa-
tion resulting from damage to the trigeminal nerve, as occurs in
individuals with neurotrophic keratopathy. Corneal sensation and
tear ﬂuid secretion are connected by the trigeminal nerve reﬂex,
with the loss of corneal sensation often being accompanied by
reduced tear secretion. The loss of corneal sensation may also give
rise to various types of corneal epithelial disorders directly as a
result of the loss of stimuli from nerve endings in the corneal
epithelium. Substance P, a sensory neurotransmitter, is present in
normal human tear ﬂuid at a concentration of ~300 pg/mL, with
this value not being dependent on age or sex. Fragments of sub-
stance P are also detected in tear ﬂuid, suggesting that this
neurotransmitter is degraded by tear enzymes (Yamada et al., 2002,
2003). In patients with corneal hypesthesia, however, the concen-
tration of substance P in tear ﬂuid is reduced to about two-thirds of
the normal value (Yamada et al., 2000).
Homeostasis of corneal epithelial structure and function is thus
maintained in large part by the actions of growth factors and neural
factors in tear ﬂuid, by signals dependent on the condition of the
basementmembrane, and by the direct effects of neurotransmitters
released from nerve endings. Furthermore, the condition of tear
ﬂuid, corneal sensation, and the ECM are important determinantsof the pathobiology of PEDs. PEDs develop in individuals with dry
eye as a result of the low quantity or quality of tear ﬂuid. They also
often emerge after recovery from corneal infections such as
herpetic keratitis and microbial keratitis. In addition, individuals
with diabetes develop diabetic keratopathy after damage to the
corneal epithelium as a result of delayed epithelial resurfacing.
Given that weak adhesion of remaining corneal epithelial cells
to the underlying provisional matrix is implicated in the pathobi-
ology of PEDs, we have focused our research on ﬁnding substrates
that might contribute to a curative treatment, bearing in mind the
key role of the adhesive glycoprotein ﬁbronectin in epithelial
resurfacing. Concepts for new drug development for PEDs thus
include both the provision of a scaffold to stimulate the adhesion
and migration of epithelial cells as well as the active promotion of
these processes through up-regulation of integrin chains that serve
as a receptor for ﬁbronectin.
3. Epithelial healing process in the cornea
3.1. Epithelial wound healing
Thoft and Friend proposed that the normal corneal epithelium is
maintained by the balance between proliferation of basal epithelial
cells (X), centripetal movement of epithelial cells (Y), and cell loss
from the corneal surface (Z) (Thoft and Friend, 1983). For the cen-
tripetal movement of epithelial cells, the presence of intact and
healthy limbal stem cells is essential. These stem cells are thus
required for repair of the damaged corneal epithelium, with
epithelial resurfacing being delayed or not occurring at all in cases
of stem cell deﬁciency.
The turnover rate of epithelial cells in the human cornea is ~1
week (Hanna et al., 1961; Hanna and O'Brien,1960), whereas that of
keratocytes and ECM in the corneal stroma is on the order of 2e3
years and corneal endothelial cells do not turn over. Epithelial
disorders should thus be resolved within ~1 week with appropriate
treatment, whereas pathologies of the stroma require a much
longer time to clear up after the resolution of acute inﬂammation.
Given the limited recovery capacity of endothelial cells, it is
important that these cells are protected from inﬂammatory attack
or other insults.
The function of corneal cells is regulated by various biologically
active humoral agents and neural factors as well as by cell-to-cell
and cell-to-matrix interactions (Imanishi et al., 2000; Suzuki
et al., 2003; Wilson et al., 2001). Soluble factors are supplied by
tear ﬂuid, aqueous humor, the limbal vascular system, and nerve
ﬁbers. In addition, cells of the corneal epithelium, stroma, and
endothelium interact with each other by cell-to-cell contact and by
secreting various biologically active substances such as growth
factors and cytokines (Ko et al., 2012, 2008a,b, 2014, 2010a,b, Ko
et al., 2009a,b). The function and fate of the corneal epithelium
are regulated predominantly by factors derived from tear ﬂuid and
nerve ﬁbers as well as by keratocytes.
The largest boundary between the body and the environment is
the skin, and the mechanism of cutaneous wound healing has been
extensively investigated. Injury to a vascularized tissue such as the
skin is followed by four phases of the healing process: (1) inﬂam-
mation (includingblood coagulation and the accumulationof blood-
derived cells such as platelets and neutrophils), (2) epithelialization,
(3) granulation, and (4) tissue remodeling (Clark, 1996; Singer and
Clark, 1999). In most parts of the body, with exceptions such as the
cornea and joints, there are blood capillaries within a distance of
50 mm from any cell. Any injury to such tissues is thus accompanied
by the breakdown of capillaries and consequent hemorrhage. The
ﬁrst step of the healing process includes the escape of blood com-
ponents into the neighboring tissue and formation of a blood clot at
Fig. 2. Molecular structure of ﬁbronectin. The various structural domains as well as binding sites for ﬁbronectin (FN), ﬁbrin, collagen, cells, and heparin are indicated. The amino
acid sequences RGD and PHSRN constitute the major binding site for integrin a5b1 and a second site that supports RGD-mediated adhesion, respectively.
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the resurfacing of the defect area and granulation of the wound
mediated by active proliferation of ﬁbroblasts.
The cornea is unique in that it contains no blood capillaries. The
initial stage of the wound healing process in the cornea thus differs
from that in skin, with the leakage of blood components and blood
clotting not occurring in the cornea. Instead, biological signals from
the injured or dead corneal cells stimulate the secretion of various
inﬂammatory cytokines from neighboring uninjured cells. In
addition to the death of corneal cells resulting directly from injury,
these newly secreted cytokines, so-called inﬂammatory cytokines,
modify the physiology of the surviving cells and thereby trigger
inﬂammation. Injuries to the cornea almost always involve the
generation of epithelial defects, and healing then proceeds with re-
epithelialization of these defects followed by a tissue remodeling
phase characterized by reassembly of the extracellular collagen
matrix in the corneal stroma. These later phases of the wound
healing process are thus common to vascularized skin and the
avascular cornea.
The healing of corneal injuries must ensure that the cornea is
transparent and has a smooth surface and the required curvature to
restore vision. In contrast, wound repair in the skin must ensure
only that the continuity and barrier function of this organ are
restored. The formation of a scar at the site of a skin injury is not a
serious problem as far as the function of the body is concerned. The
healing of the cornea is thus a far more delicate and precise process.3.2. Fibronectineintegrin interactions in corneal epithelial wound
healing
Asmentioned above, PEDs of the cornea are characterized by the
loss of attachment of remaining corneal epithelial cells and by
impaired epithelial migration. The absence of an appropriatesubstrate on which epithelial cells can attach and migrate thus
appears central to the pathology of PEDs. With the goal of devel-
oping new drugs to treat this problem, we have focused on the
substrate, cell attachment, and cell migration associated with the
healing of corneal epithelial damage.3.2.1. The ﬁbronectineintegrin system
Fibronectin is a 440-kDa glycoprotein that comprises two
identical chains connected by disulﬁde bonds. It functions as an
adhesive protein and plays central roles in many biological pro-
cesses involving cell adhesion, detachment, and migration. It thus
contributes to wound healing, embryogenesis, development, and
cancer metastasis (Hynes, 1990; Pankov and Yamada, 2002).
Fibronectin is localized to the ECM and is also present in blood
plasma. Fibronectin in human plasma is synthesized by hepato-
cytes and is present as a soluble dimer at a concentration of
~300 mg/mL (Mosesson and Amrani, 1980; Mosesson and Umﬂeet,
1970; Mosher and Williams, 1978; Nishida et al., 1982a). Plasma
ﬁbronectin was originally identiﬁed as a cold-insoluble globulin
during fractionation of blood components (Morrison et al., 1948).
Insoluble cellular ﬁbronectin is a component of the ECM. Cellular
ﬁbronectin is synthesized as a soluble dimer, mainly by ﬁbroblasts
but also by other cell types. After its secretion into the extracellular
environment, ﬁbronectin is assembled into an insoluble ﬁbrillar
matrix (Leiss et al., 2008; Mao and Schwarzbauer, 2005;
Wierzbicka-Patynowski and Schwarzbauer, 2003).
In addition to its integrin receptor, ﬁbronectin has been found to
bind to other ECM components (including collagen, gelatin, ﬁbrin,
heparin, heparan sulfate, and proteoglycans), to bacteria and vi-
ruses (including Staphylococcus aureus, Staphylococcus epidermidis,
and retroviruses), to blood components (including ﬁbrinogen and
factor XIII), and to other proteins such as insulin-like growth factor
binding protein 3 (IGFBP3) and transglutaminase. The binding of
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ized at the molecular level.
The molecular structure of ﬁbronectin is characterized by the
presence of three types of module, including 12 type I modules, 2
type II modules, and 15 type III modules (Hynes, 1990; Pankov and
Yamada, 2002) (Fig. 2). In addition, there are alternatively spliced
extra domains: EDB, EDA, and a variable region (IIICS). The binding
of ﬁbronectin to itself converts the soluble form of the protein into
the insoluble ﬁbrillar form. This self-assembly process thus con-
tributes to formation of the insoluble ﬁbronectin meshwork pre-
sent in the extracellular environment. Fibronectin has at least two
cell adhesion sites. The major cell-binding site of ﬁbronectin is the
amino acid sequence ArgeGlyeAsp (RGD) in the 10th type III
domain. This sequence thus interacts with the integrin receptor at
the cell surface. The amino acid sequence ProeHiseSereArgeAsn
(PHSRN) in the ninth type III domain of ﬁbronectin has also been
found to support cell adhesion mediated by the RGD motif.
Integrins are transmembrane heterodimeric proteins that
function as the receptors for various ECM proteins. They are
composed of a and b subunits, with at least 18 a subunits and 8 b
subunits having been identiﬁed in humans. The binding of integrins
to ECM proteins such as ﬁbronectin, collagen, laminin, tenascin, and
ﬁbrinogen serves to link these external proteins to the internal
cytoskeleton of cells. Integrin a5b1 is the predominant cell surface
receptor for ﬁbronectin.
Integrins have two major physiological functions. First, they
mediate the attachment of cells to the ECM. Second, they transmit
signals from the outside to the inside of cells. Depending on the
type of ECM protein and corresponding integrin involved, the
receptoreligand interaction results in the activation of various
intracellular signaling pathways that contribute to the regulation of
cell behavior including cell survival, differentiation, proliferation,
and migration (Das et al., 2014; Epifano and Perez-Moreno, 2012;Fig. 3. Effects of ﬁbronectin on the distribution of b-Pix and on the actin cytoskeleton in HCE
rhodamine-phalloidin (red, for detection of F-actin), with antibodies to b-Pix or to phospho
Reproduced with permission from Kimura et al. (2011).Hynes, 1987, 2002; Labat-Robert, 2012; Longmate and Dipersio,
2014; Margadant et al., 2010; Parapuram et al., 2011; Stepp, 2006;
Stepp et al., 1993).
3.2.2. The ﬁbronectineintegrin system in corneal epithelial wound
healing
The ﬁbronectineintegrin system is critical for the attachment,
migration, and differentiation of corneal epithelial cells. In the
normal nonwounded cornea, ﬁbronectin is localized predomi-
nantly to Descemet's membrane, the basement membrane of the
epithelium, and the stroma (Fujikawa et al., 1981; Kohno et al.,
1987; Sramek et al., 1987; Suda et al., 1981; Tervo et al., 1986). On
the other hand, expression of the major ﬁbronectin receptor,
integrin a5b1, is restricted to the basal cells of the epithelium in the
intact cornea (Grushkin-Lerner and Trinkaus-Randall, 1991; Lau-
weryns et al., 1991; Murakami et al., 1992; Paallysaho andWilliams,
1991; Stepp et al., 1993; Tervo et al., 1991).
Abrasion of the corneal epithelium is followed by the appear-
ance of ﬁbronectin in the exposed stroma and its subsequent
gradual disappearance as healing proceeds (Fujikawa et al., 1981).
Fibronectin also appears at the cut surface of the stroma and
epithelial cells migrate over the deposited ﬁbronectin in response
to a nonpenetrating injury to the cornea (Suda et al., 1981). The
ﬁbronectin gradually disappears soon after the epithelial cells
have covered the exposed stroma. All actively migrating epithelial
cells, from basal to superﬁcial cells, express integrin a5b1 after
injury. As the epithelial defect is resurfaced, however, only basal
epithelial cells facing the newly synthesized basement membrane
express integrin a5b1 (Murakami et al., 1992). This well-
coordinated appearance and disappearance of ﬁbronectin and
integrin in the corneal stroma and epithelial cells, respectively,
suggest that the ﬁbronectineintegrin system plays a central role in
corneal epithelial wound healing. Indeed, various types of cornealcells. Cells plated on ﬁbronectin (FN) or bovine serum albumin (BSA) were stained with
tyrosine (green), and with TOTO-3 (blue, for detection of nuclei). Scale bar, 10 mm.
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stroma and thereby contribute to epithelial wound healing
(Fujikawa et al., 1984; Nishida et al., 1982c; Ohashi et al., 1983;
Spigelman et al., 1985). This provisional ﬁbronectin matrix pro-
vides a substrate for the migration of epithelial cells, with integrin
expression in the epithelial cells allowing the cells to bind to the
ﬁbronectin and the ﬁbronectineintegrin interaction signaling the
cells to migrate. In addition to ﬁbronectin, ﬁbrineﬁbrinogen ap-
pears to be an essential component of the provisional matrix,
whereas laminin and type IV collagen are not present (Fujikawa
et al., 1984).
3.3. Responses of corneal epithelial cells to ﬁbronectin
3.3.1. Cell attachment, spreading, and migration on a ﬁbronectin
matrix
As already mentioned, ﬁbronectin is an adhesive glycoprotein
that is essential for the attachment and spreading of corneal
epithelial cells during corneal epithelial wound healing (Nakamura
and Nishida, 1994a; Suzuki et al., 2003). The number of corneal
epithelial cells that attach to a culture plate coated with ﬁbronectin
increases in proportion to the concentration of coated ﬁbronectin
(Nishida et al., 1988). Fibronectin stimulates epithelial cell migra-
tion as a result of its chemotactic, haptotactic, and chemokinetic
activities (Watanabe et al., 1988).
A ﬁbronectin substrate also stimulates the spreading of rabbit
corneal epithelial cells, with the area of spreading depending on the
concentration of ﬁbronectin used to coat a culture plate in vitro. In
spread cells, stress ﬁbers of actin ﬁlaments are evenly distributed
throughout the cytoplasm, whereasmicrotubules are apparent only
in the perinuclear region. The presence of cytochalasin B (an in-
hibitor of actin polymerization) during corneal epithelial cell
attachment and spreading on ﬁbronectin was found to reduce the
area of spreading to a greater extent than did the presence of
colchicine (an inhibitor of microtubule polymerization). However,
the addition of either agent after cell spreading had only a small
effect on the spread area. These observations thus indicate that the
formation of actin ﬁlaments is more important than that of mi-
crotubules for corneal epithelial cell spreading (Fukuda et al., 1990).
The attachment of simian virus 40-transformed human corneal
epithelial (HCE) cells to ﬁbronectin induces the accumulation of
ﬁlamentous (F) actin and the formation of focal adhesions at the
cell periphery as well as activation of the small GTPase Rac1,
phosphorylation of p21-activated kinase (PAK), and localization of
the Kþ channel Kv2.1 to the leading edge of the cell in the direction
of cell migration (Kimura et al., 2006, 2010). Fibronectin also in-
duces tyrosine phosphorylation of the Cdc42-and Rac-speciﬁc
guanine nucleotide exchange factor b-Pix in, as well as active
rufﬂing at the leading edge of, these cells (Kimura et al., 2011)
(Fig. 3).
Rabbit corneal epithelial cells respond differently to different
matrix components such as ﬁbronectin, collagen types I and IV, and
laminin. Freshly isolated (uncultured) cells did not spread on
ﬁbronectin or laminin but did so on collagen types I and IV. After
culture of the cells for 12 h or more, however, they also spread on
ﬁbronectin, whereas spreading of the cells on collagen types I and
IV was the same regardless of the culture period (up to 20 h). Only a
small number of cells spread on laminin at the highest concentra-
tion examined even after culture for 12 h or more. These observa-
tions with ﬁbronectin suggested that ﬁbronectin receptors are up-
regulated during culture (Nakagawa et al., 1990). Attachment of
corneal epithelial cells to ﬁbronectin was inhibited in a
concentration-dependent manner by addition to the culture me-
dium of the synthetic peptide GRGDS, corresponding to the major
cell-binding site of ﬁbronectin, whereas the structurally similarcontrol peptide GRGES had no such effect (Nishida et al., 1988).
Corneal epithelial cells thus bind to a ﬁbronectin substrate via the
RGD site of ﬁbronectin.
Among the major components of basement membrane, laminin,
ﬁbronectin, and collagen types I and IV each promote the adhesion
of HCE cells compared with bovine serum albumin as an inactive
control. Fibronectin and collagen types I and IV, but not laminin,
also increase the motility of these cells. Whereas collagen types I
and IV each increase membrane movement in a manner indepen-
dent of the direction of cell migration, ﬁbronectin induces mem-
brane movement only in the direction of cell migration. Fibronectin
also induces the formation of thick bundles of F-actin and focal
adhesions at the cell periphery as well as the localization of Kv2.1 at
the leading edge of the cell, whereas laminin and collagen types I
and IV elicit the formation of thinner bundles of F-actin and smaller
focal adhesions and do not affect the localization of Kv2.1. Fibro-
nectin thus modulates the directional migration of corneal
epithelial cells as well as cell attachment and spreading (Kimura
et al., 2010). In addition to exogenous ﬁbronectin, newly synthe-
sized endogenous ﬁbronectin was found to contribute to the
attachment of human corneal epithelial cells in culture (Ohji et al.,
1993). Hyaluronan binds to a ﬁbrin and heparin binding domain at
the amino terminus of plasma ﬁbronectin and may thereby in-
crease the afﬁnity of ﬁbronectin for cells, resulting in the facilitation
of corneal epithelial cell attachment to ﬁbronectin (Nakamura et al.,
1994).
The effects of various growth factors and cytokines on the
attachment and spreading of corneal epithelial cells have been
investigated. EGF thus facilitates corneal epithelial resurfacing
in vivo as well as promotes corneal epithelial cell attachment to
ﬁbronectin in vitro. This EGF-stimulated cell attachment to ﬁbro-
nectin was inhibited in a concentration-dependent manner by
antibodies to ﬁbronectin as well as by the GRGDSP peptide,
implicating the ﬁbronectineintegrin system in this effect of EGF.
Indeed, EGF increases the expression of integrin a5b1 in these cells
(Nishida et al., 1992b). Interleukin (IL)-6 and the combination of
substance P and IGF-1 was also found to up-regulate integrin a5b1
expression in corneal epithelial cells (Chikama et al., 1999;
Nakamura et al., 1998a; Ohashi et al., 1995).
3.3.2. Promotion of corneal epithelial migration by ﬁbronectin
We investigated whether ﬁbronectin stimulates migration of
the corneal epithelium with the use of an organ culture system for
the rabbit cornea, in which pieces of full-thickness cornea are
cultured for 24 h with test agents (Nishida et al., 1983a). Immu-
noﬂuorescence analysis revealed the appearance of ﬁbronectin at
the surface of the cut stroma as well as beneathmigrating epithelial
cells (Nishida et al., 1982b), indicating that such ﬁbronectin origi-
nates in the cornea itself. The addition of puriﬁed plasma ﬁbro-
nectin to the culturemedium increased the path length of epithelial
migration in a concentration- and time-dependent manner,
showing that exogenous ﬁbronectin stimulates epithelial migration
(Nishida et al., 1983a).
EGF facilitates corneal epithelial wound healing (Daniele et al.,
1979; Ho and Elliott, 1975), and we found that EGF also enhanced
migration of the corneal epithelium in our organ culture system.
The mechanism of action of EGF appeared to differ from that of
ﬁbronectin, however. Whereas ﬁbronectin promoted sliding of the
epithelium, EGF stimulated epithelial cell proliferation (Watanabe
et al., 1987). EGF also up-regulated the synthesis of ﬁbronectin by
the cultured cornea (Nishida et al., 1984b). The stimulatory effect of
EGF on corneal epithelial migration thus showed a time lag of at
least 12 h, whereas that of ﬁbronectin was essentially immediate.
The maximal effect of ﬁbronectin required its continuous presence.
In contrast, whereas exposure to EGF for 6 h did not stimulate
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latory effect as did that for 24 h. Antibodies to ﬁbronectin inhibited
both the ﬁbronectin- and EGF-stimulated migration of the corneal
epithelium, whereas antibodies to EGF inhibited EGF-stimulated
migration but not that induced by ﬁbronectin. These results indi-
cate that, unlike ﬁbronectin, EGF need not be present after the
epithelial cells have recognized its signal, and that the stimulatory
effect of EGF is dependent on ﬁbronectin whereas that of ﬁbro-
nectin is independent of EGF (Nishida et al., 1990). As mentioned
earlier, EGF also up-regulates the expression of integrin a5b1 in
cultured rabbit corneal epithelial cells (Nakamura and Nishida,
1994b; Nishida et al., 1992b). In addition to EGF, IL-6 stimulated
corneal epithelial migration in our organ culture system in a
manner dependent on ﬁbronectin, presumably at least in part as a
result of its up-regulation of integrin a5b1 expression (Nishida
et al., 1992a; Ohashi et al., 1995).
Before the application of ﬁbronectin eyedrops to patients could
be considered, we examined the effects of such eyedrops in ani-
mals. The administration of rabbit plasma ﬁbronectin (0.75 mg/mL)
to the cornea of rabbits subjected to epithelial debridement with
the use of iodine vapor was found to accelerate epithelial resur-
facing signiﬁcantly compared with that observed after application
of control phosphate-buffered saline eyedrops (Nishida et al.,
1984a). Administration of ﬁbronectin eyedrops was also effective
in promoting corneal epithelial wound healing in vitamin A-deﬁ-
cient rats (Watanabe et al., 1991) and in rats with streptozotocin-
induced diabetes (Nakamura et al., 1997d), in both of which
epithelial resurfacing is delayed.4. Provision of a ﬁbronectin substrate for promotion of
epithelial migration in PEDs
Fibronectin plays an essential role in corneal epithelial wound
healing by serving as a provisional matrix for the adhesion and
migration of epithelial cells. Given that ﬁbronectin might be
degraded in the inﬂammatory lesion of corneal PEDs, it seemed
possible that the administration of exogenous ﬁbronectin to the
damaged corneal epithelium might help to accomplish epithelial
resurfacing in the clinical setting.Fig. 4. Autologous ﬁbronectin eyedrops for the treatment of corneal PEDs. Photo-
graphs (upper panels) and slitlamp microscopic images of ﬂuorescein staining (lower
panels) for a patient with PEDs both before (left panels) and 1 week after (right panels)
the initiation of treatment with autologous ﬁbronectin eyedrops.4.1. Autologous ﬁbronectin eyedrops
A pure preparation of biologically active ﬁbronectin was not
available commercially in the early 1980s. Fibronectin is present in
human blood plasma at a concentration of ~300 mg/mL (Labat-
Robert et al., 1981; Mosher and Williams, 1978; Nishida et al.,
1982a; Soria et al., 1980), and it binds strongly to gelatin, or dena-
tured collagen (Engvall and Ruoslahti, 1977).With the use of gelatin
afﬁnity chromatography, we were therefore able to purify ﬁbro-
nectin from blood plasma and to prepare ﬁbronectin eyedrops
within 1 h (Nishida et al., 1982a). To avoid any unfavorable and
unexpected effects, we obtained the blood plasma from the patient
who was going to be treated with the ﬁbronectin eyedrops. Given
the prevalence of blood-borne viral infections, such as those caused
by hepatitis viruses and HIV, this approach remains the safest even
today.
We initially treated three eyes of two patients with puriﬁed
autologous ﬁbronectin eyedrops. Both patients had PEDs of the
cornea that had proved unresponsive to conventional therapy. In
each case, re-epithelialization of the cornea began within 3 days,
and the defects had disappeared completely within 3 weeks
(Nishida et al., 1983c). We subsequently treated 20 cases of non-
healing epithelial defects secondary to herpetic keratitis by the
administration of ﬁbronectin eyedrops six times a day. The duration
of the epithelial defects was 61.5 ± 66.1 days (mean± SD) before the
treatment, and the defects healed within 15.6 ± 12.4 days (Nishida
et al., 1985). Autologous plasma ﬁbronectin eyedrops were thus
instituted for the treatment of corneal epithelial disorders at
Yamaguchi University Hospital. Our clinical experience with 151
eyes of 146 patients between April 2000 and March 2005
conﬁrmed that ﬁbronectin eyedrops are effective for the treatment
of corneal PEDs (72% of 100 eyes responded with complete
epithelial resurfacing within 9.5 ± 6.8 days) and simple corneal
erosion (91.4% of 35 eyes responded with complete resurfacing
within 7.0 ± 6.4 days) (Nishida, 2012). A representative case is
shown in Fig. 4. The clinical efﬁcacy of such ﬁbronectin treatment
has also been reported by others (Kim et al., 1990; McCluskey et al.,
1987; Phan et al., 1987). We have also successfully applied autolo-
gous ﬁbronectin eyedrops to the treatment of recurrent corneal
erosion (Nishida et al., 1983b), whereas others (Boisjoly and
Beaulieu, 1991) did not ﬁnd autologous ﬁbronectin to be effective
for the treatment of this condition.
More recently, we have administered autologous ﬁbronectin
eyedrops to provide a provisional matrix after epithelial debride-
ment in severe cases of ocular allergic disease, recurrent corneal
erosion, and lattice corneal dystrophy (Fukuda et al., 2010; Morita
et al., 2012). This is an adjunct use of ﬁbronectin to achieve a
rapid and complete epithelial resurfacing after the surgery. Appli-
cation of ﬁbronectin after refractive surgeries might also facilitate
rapid restoration of the corneal epithelium.
4.2. Homologous ﬁbronectin eyedrops
Randomized, double-blind clinical trials of homologous ﬁbro-
nectin eyedrops for the treatment of PEDs were performed
nationwide in Japan in the early 1990s. Fibronectin eyedrops were
prepared from human blood plasma at the New York Blood Center,
and virus inactivation was performed to prevent infection. At a
concentration of 0.75 mg/mL, ﬁbronectinwas found to signiﬁcantly
improve healing. Further drug development was halted, however,
because of a requirement from the Japanese health agency for proof
of an absolute lack of viral contamination. No trials with homolo-
gous ﬁbronectin eyedrops have since been conducted in Japan.
Phase II and III clinical trials of homologous ﬁbronectin eyedrops
for corneal PEDs were performed in the United States (McCulley
T. Nishida et al. / Progress in Retinal and Eye Research 47 (2015) 38e6348et al., 1993). However, whereas clinical efﬁcacy was demonstrated
in the phase II trial, it was not apparent in the phase III study. The
protocols for the two studies were a little different, with the
ﬁbronectin eyedrops containing a preservative in the phase III trial
but not in the phase II trial. Furthermore, homologous ﬁbronectin
was compared in the phase III study with frequent application of
ointment as the standard treatment. It was thus likely that ﬁbro-
nectin could not overcome the toxicity of the preservative in PED
patients. Chiron Ophthalmics also conducted a randomized,
double-blind phase II trial of homologous human plasma ﬁbro-
nectin eyedrops containing a preservative for PEDs in the United
States. Again, clinical efﬁcacy of the eyedrops was not demon-
strated (Gordon et al., 1995). These studies thus suggest that ho-
mologous ﬁbronectin may have efﬁcacy for the treatment of certain
types of eye pathology but that the concentration, preservative, and
frequency of administration need to be optimized.
4.3. Prospects for ﬁbronectin eyedrops
The ﬁbronectineintegrin system plays a central role in corneal
epithelial wound healing. The administration of autologous ﬁbro-
nectin eyedrops appears to be clinically effective for the resurfacing
of corneal epithelial defects, with the exogenous ﬁbronectin being
adsorbed onto the exposed surface of either the stroma or base-
ment membrane and providing a provisional matrix to support
both the adhesion and migration of corneal epithelial cells.
It has proven difﬁcult, however, to demonstrate the clinical ef-
ﬁcacy of homologous ﬁbronectin eyedrops for the treatment of
PEDs. These defects and their underlying causes differ among pa-
tients, and it is difﬁcult to enroll patients whose epithelial defects
may persist or resurface rapidly before entry into a clinical trial. The
concomitant administration of various types of eyedrops with
preservatives may also delay epithelial wound closure, with the
defects of some patients healing during the washout period
(Gordon et al., 1995).
On the basis of our clinical experience over 3 decades and the
results of clinical trials performed in both Japan and the United
States, we believe that there is no intrinsic difference between
autologous and homologous ﬁbronectin eyedrops. The major
concern is that ﬁbronectin is prepared from blood, and that the
possibility of contamination with blood-borne viruses or other
deleterious factors cannot be ruled out. Given that ﬁbronectin
eyedrops are not available commercially, most ophthalmologists
are not able to prescribe them. Biochemical knowledge and skill are
required to prepare ﬁbronectin eyedrops from a patient's own
blood plasma. Although, as far as we are aware, use of autologous
ﬁbronectin is safe, the potential problem of contamination exists
for homologous ﬁbronectin prepared from pooled blood. We are
still using the original technique to prepare autologous ﬁbronectin
eyedrops for the treatment of corneal epithelial disorders at
Yamaguchi University Hospital. Given that ﬁbronectin is a large
glycoprotein, it is currently extremely difﬁcult to synthesize ﬁbro-
nectin by genetic engineering technology, although recombinant
human ﬁbronectin might become available for clinical use in the
not too distant future.
4.4. Autologous serum eyedrops
The application of autologous serum eyedrops has been
accepted widely. Growth factors, cytokines, ﬁbronectin, and vita-
mins that are essential for the maintenance and continuous healing
of the corneal epithelium are present in blood serum as well as in
tear ﬂuid (Bradley et al., 2008). Deﬁciency of such biologically active
substances contributes to the pathobiology of various types of
corneal epithelial disturbances (Imanishi et al., 2000; Klenkler andSheardown, 2004; Klenkler et al., 2007). The administration of
blood serum eyedrops to patients with severe corneal epithelial
disorders in order to replenish these active substances is thus
theoretically well grounded. In 1984, Fox and colleagues reported a
beneﬁcial effect of autologous serum eyedrops in patients with dry
eye (Fox et al., 1984). Subsequently, Tsubota and associates as well
as others found that such eyedrops were effective for the treatment
of severe dry eye and neurotrophic keratopathy (Fox et al., 1984;
Geerling et al., 2004; Kojima et al., 2008; Matsumoto et al., 2004;
Noda-Tsuruya et al., 2006; Poon et al., 2001; Tsubota et al.,
1999a,b; Tsubota and Higuchi, 2000). Randomized clinical trials
provided further evidence for beneﬁcial effects of autologous
serum in patients with severe ocular surface disorders (Noble et al.,
2004; Tananuvat et al., 2001; Urzua et al., 2012). However, the
clinical improvement described in these various studies was mostly
based on subjective assessment. At present, there is no direct evi-
dence to support a beneﬁcial effect of autologous serum eyedrops
(Pan et al., 2013). As we described in our report of the ﬁrst suc-
cessful application of autologous ﬁbronectin eyedrops, we ﬁrst
administered autologous serum eyedrops for 1 week after the
diagnosis of trophic ulcer with no beneﬁcial effect (Nishida et al.,
1983c). It is thus possible that serum also contains inhibitory fac-
tors that block the stimulatory effect of serum ﬁbronectin on
corneal epithelial wound healing. Foulks (2003) commented that
“Identiﬁcation of the speciﬁc molecules responsible for the healing
effect of serum may allow more speciﬁcally targeted therapy in the
future.” As addressed in the next section, we have identiﬁed pep-
tides derived from ﬁbronectin, substance P, and IGF-1 as candidates
for the implementation of such targeted therapy.
5. Activation of epithelial cells to facilitate their migration by
peptides
As we have described above, ﬁbronectin facilitates migration of
the corneal epithelium both in vitro and in vivo. Although ﬁbro-
nectin eyedrops have been found to be effective for the treatment of
nonhealing epithelial defects of the cornea, such eyedrops are not
available commercially, largely because ﬁbronectin is puriﬁed from
blood plasma and it is impossible to eliminate the possibility of
contaminationwith blood-borne viruses. Given that the production
of recombinant ﬁbronectin is not yet feasible, an alternative
approach to overcoming these problems is to identify an active
motif of the ﬁbronectin molecule for use as a synthetic peptide in
the clinic.
5.1. The ﬁbronectin-derived peptide PHSRN
5.1.1. Identiﬁcation of PHSRN as a synergy site for the binding of
ﬁbronectin to integrin
The complete primary structure of human ﬁbronectin was re-
ported in 1985 (Kornblihtt et al., 1985), and that of bovine plasma
ﬁbronectin in 1986 (Skorstengaard et al., 1986). Since then, the
relation between the molecular structure and biological function of
ﬁbronectin has been extensively investigated (Pankov and Yamada,
2002; Schwarzbauer, 1991).
The ArgeGlyeAsp (RGD) amino acid sequence in 10th type III
domain of ﬁbronectin is the main site responsible for binding to the
cell surface (Pierschbacher and Ruoslahti, 1984), a ﬁnding that led
to the discovery of integrins. In addition to this RGD sequence,
however, the ProeHiseSereArgeAsn (PHSRN) sequence in the
adjacent 9th type III domain of ﬁbronectin synergistically enhances
binding to cells mediated by the RGD sequence and integrin a5b1
(Aota et al., 1994) (Fig. 2). The requirement for the PHSRN synergy
site in a5b1-mediated adhesion to the RGD sequence of ﬁbronectin
depends on the activation state of the integrin (Danen et al., 1995).
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a5b1eﬁbronectin interface, and the synergy site provides me-
chanical strength to the interaction (Garcia et al., 2002). The PHSRN
synergy site is more complex than the small linear RGD peptide
sequence (Redick et al., 2000). A mechanism for integrin
a5b1eﬁbronectin interaction, which, in addition to the primary
RGD binding event, involves a conformation-sensitive binding of
the integrin to accessible sites on the ligand, resulting in full acti-
vation of downstream signaling, has been proposed (Altroff et al.,
2001).
A balance between peptide density and steric accessibility of the
receptor-binding sequence to integrin a5b1 is required for the
strongest adhesion (Dillo et al., 2001). Indeed, addition of soluble
PHSRN peptide together with the RGD peptide did not show a
synergistic effect on cell adhesion, whereas the conjugation of
these peptides to an amino acid-type poly(ethylene glycol) deriv-
ative (aaPEG) revealed that the PHSRN sequence in the
PHSRNeaaPEGeRGD molecule synergistically enhanced the cell
spreading activity of the RGD sequence (Hojo et al., 2001).5.1.2. Physiological activities of PHSRN
An acetylated and amidated form of the PHSRN peptide (Ac-
PHSRN-amide) was found to stimulate the invasion of mouse
keratinocytes and ﬁbroblasts into ECM of sea urchin embryos
(Livant et al., 2000). A randomized peptide sequence, Ac-HSPNR-
amide, as well as forms of the original peptide in which Arg is
replaced by either Ala or Glu were inactive in this assay. Topical
application of Ac-PHSRN-amide also accelerated dermal wound
healing in genetically obese, diabetic (C57BL6/KsJ db/db) mice, in
which wound healing is delayed compared with that in control
(C57BL6) mice. The peptide Ac-PHSCN-amide was found to inhibit
both PHSRN- and serum-induced invasion of prostate carcinoma
cells in vitro in a competitive manner, and intravenous injection of
Ac-PHSCN-amide signiﬁcantly inhibited tumor growth and neo-
vascularization in vivo, suggesting that this peptide may be a
potent antitumorigenic and antimetastatic agent (Livant et al.,
2000).
Synergy between the RGD and PHSRN sequences of ﬁbronectin
is important for macrophage adhesion, with these two peptides
having been found to recapitulate the activity of the full-length
ﬁbronectin molecule. Macrophage adhesion to an oligomer con-
taining both RGD and PHSRN sequences (GGGRGDG
GGGGGPHSRNG) was found to be mediated by activation of both
protein kinase C (PKC) and extracellular signal-regulated kinase
(ERK) signaling pathways (Kao and Lee, 2001; Kao et al., 2001; Kao
and Liu, 2001). The interaction of ﬁbronectin with integrin a5b1 in
monocytes stimulates the production of angiogenic CXC chemo-
kines (including IL-8, epithelial neutrophil-activating peptide-78,
growth-related oncogene a, and growth-related oncogene g) but
not that of vascular endothelial growth factor (White et al., 2001).5.1.3. Effects of PHSRN on corneal epithelial cells
We have investigated the effects of the synthetic peptide Ac-
PHSRN-amide on corneal epithelial migration both in vitro and
in vivo. We found that exogenous Ac-PHSRN-amide stimulated
corneal epithelial migration in our organ culture system for the
rabbit cornea in a concentration-dependent manner. The stimula-
tory effect of Ac-PHSRN-amide at 0.2 or 2 mM was identical to that
of either human plasma ﬁbronectin at 0.1 mM or recombinant hu-
man EGF at 0.1 mM. The reverse-sequence peptide, Ac-NRSHP-
amide, was inactive in this assay. The addition of Ac-PHSRN-
amide (2 mM) to HCE cells in culture also increased cell motility
in association with the formation of membrane rufﬂes at the cell
periphery (Kimura et al., 2007).We examined the sequence speciﬁcity of the effect of PHSRN on
corneal epithelial migration. Elongation and deletion analyses of
Ac-PHSRN-amide indicated that the ﬁve-amino acid sequence
(PHSRN) was the minimum essential sequence for promotion of
corneal epithelial migration. Alanine substitution analysis revealed
that the Ser and Arg residues are critical for the biological activity of
PHSRN. Furthermore, the N-acetyl and C-amide groups of Ac-
PHSRN-amide are important for the chemical stability of the pep-
tide in tear ﬂuid (Hattori et al., 2009). These ﬁndings thus suggested
that Ac-PHSRN-amide had therapeutic potential for the promotion
of corneal wound healing.
We also examined the effect of the PHSRN peptide on HCE cell
adhesion to a ﬁbronectin matrix. Neither PHSRN nor NRSHP at
concentrations of 1e1000 mM had a signiﬁcant effect on cell
adhesion to ﬁbronectin. In contrast, the GRGDSP peptide, but not
the control GRGESP peptide, inhibited adhesion of HCE cells to
ﬁbronectin in a concentration-dependent manner (Kimura et al.,
2007).
Immortalized rabbit corneal epithelial cells adhere to a chemi-
cally synthesized collagen-like polypeptide, poly(-
prolylehydroxyprolyleglycyl), or poly(ProeHypeGly). Conjugation
of GRGDS to poly(ProeHypeGly) increased the adhesion of corneal
epithelial cells to the polypeptide, and conjugation of both GRGDS
and PHSRN increased adhesion even further. The addition of solu-
ble GRGDS inhibited adhesion of the epithelial cells to ﬁbronectin,
whereas that of soluble PHSRN had a smaller inhibitory effect.
These results thus conﬁrmed the key role of the RGD sequence and
the secondary role of the PHSRN sequence in the adhesion of
corneal epithelial cells to ﬁbronectin (Shibasaki et al., 2011).
We found that the PHSRN peptide induced the formation of a
thick rim of actin ﬁlaments in a dense meshwork at the leading
edge of HCE cells. Co-staining with antibodies to phosphotyrosine
revealed numerous small dotlike structures, presumably corre-
sponding to focal adhesions, associated with the bundles of F-actin
at the cell periphery. Immunoblot analysis showed that the PHSRN
peptide increased the tyrosine phosphorylation of both focal
adhesion kinase (FAK) and paxillin in HCE cells compared with that
apparent in the presence of the NRSHP peptide (Kimura et al.,
2007). PHSRN also increased the levels of HSP70 (heat shock pro-
tein of 70 kDa) mRNA and protein in these cells in a concentration-
and time-dependent manner, whereas NRSHP did not. The PHSRN-
induced up-regulation of HSP70 was blocked by SB203580, an in-
hibitor of p38 mitogen-activated protein kinase (MAPK), but it was
not affected by PD98059 or SP600125, inhibitors of signaling by the
MAPKs ERK and c-Jun NH2-terminal kinase (JNK), respectively (Ko
et al., 2008c). These results suggested that the induction of HSP70
expression might contribute to the promotion of corneal epithelial
migration by PHSRN and hence to corneal epithelial wound healing.
Furthermore, PHSRN increased the expression of the tight-junction
protein ZO-1 (zonula occludens-1) at both mRNA and protein levels
and in a concentration- and time-dependent manner in HCE cells,
whereas it had no effect on that of the tight-junction proteins ZO-2,
ZO-3, claudin, or occludin. Immunoﬂuorescence microscopy
showed that the PHSRN peptide did not affect the localization of
ZO-1 at the interfaces of neighboring cells. The up-regulation of ZO-
1 expression by PHSRN was blocked by inhibitors of ERK
(PD98059), p38 (SB203580), and JNK (JNK inhibitor II) signaling,
consistent with the ﬁnding that the peptide induced the phos-
phorylation of these MAPKs as well as that of c-Jun. The PHSRN
peptide had no effect on the transepithelial electrical resistance of
cultured HCE cells. The PHSRN peptide thus induced expression of
ZO-1 in a manner dependent on MAPK signaling, and this effect
may contribute to the formation of tight junctions between corneal
epithelial cells during their differentiation and after their migration
during wound healing (Yanai et al., 2009).
Fig. 5. PHSRN eyedrops for the treatment of corneal PEDs. Photographs (upper panels) and slitlamp microscopic images of ﬂuorescein staining (lower panels) for a patient with
PEDs both before (left panels) as well as 3 (center panels) and 17 (right panels) days after the initiation of treatment with Ac-PHSRN-amide eyedrops.
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Administration of the Ac-PHSRN-amide peptide in eyedrops
promoted corneal epithelial wound closure in rabbits in a dose-
dependent manner, whereas the control peptide Ac-NRSHP-
amide had no such effect (Kimura et al., 2007). These observa-
tions suggested that the PHSRN peptide mimics the effect of
ﬁbronectin on this process and may prove suitable as a substitute
for ﬁbronectin in the treatment of PEDs of the cornea.
On the basis of our in vitro and in vivo results with the PHSRN
peptide, we undertook a clinical study at Yamaguchi University
Hospital. Eyedrops containing Ac-PHSRN-amide (0.02%) in
phosphate-buffered saline were administered four times a day to
seven patients with PEDs. The duration of the PEDs before treat-
ment was 7.4 ± 5.5 (mean ± SD) weeks. Five out of the seven
treated eyes (71%) responded well to the regimen, with complete
epithelial resurfacing being achieved within 4 weeks after treat-
ment initiation. Indeed, the time required for complete epithelial
resurfacing in the ﬁve responding subjects was 15.8 ± 3.4 days. No
adverse effects of the treatment were observed in any of the
subjects. A representative case is shown in Fig. 5. This open clinical
study demonstrated that eyedrops containing the ﬁbronectin-
derived peptide Ac-PHSRN-amide are clinically effective for the
treatment of PEDs (Yamada et al., 2012). This ﬁnding will require
conﬁrmation by a well-controlled, double-masked, multicenter
clinical trial before the treatment can be established for patients
with PEDs.
The mechanisms of action of ﬁbronectin and the PHSRN peptide
in the promotion of corneal epithelial wound healing appear to be
completely different. Administration of ﬁbronectin provides a
provisional matrix for epithelial migration, with the RGD motif of
the exogenous ﬁbronectin binding to integrin and activating
intracellular signaling that leads to the active movement of the
epithelial cells. On the other hand, administration of the PHSRN
peptide results in modulation of the binding of cell surface integrin
to the RGD motif of endogenous ﬁbronectin. Whether or not the
concomitant administration of ﬁbronectin as a matrix together
with the PHSRN peptide as a modulator might be more effective
than treatment with either agent alone warrants further investi-
gation in the clinical setting.
5.2. Substance P and IGF-1
5.2.1. Clinical basis for study of substance P
During our treatment of patients with PEDs of the cornea by the
administration of autologous ﬁbronectin eyedrops, we recognizedthat most of these patients manifested a reduced corneal sensation.
This clinical experience led us to investigate the role of corneal
innervation by the trigeminal nerve in corneal epithelial wound
repair.
The cornea is innervated by the ophthalmic branch of the tri-
geminal nerve. It is also the most sensitive tissue of the body
(Marfurt et al., 2010; Muller et al., 2003), with the density of nerve
endings at the surface of the human cornea being ~6500/mm2,
which is 300e400 times as high as that in the skin (de Castro et al.,
1998; Muller et al., 1997; Rozsa and Beuerman, 1982). Immuno-
histological studies have revealed the presence of various neuro-
transmitters in the cornea including substance P, calcitonin gene-
related peptide (CGRP), and acetylcholine (Beckers et al., 1993;
Ehinger et al., 1983; Keen et al., 1982; Kuwayama and Stone,
1987; Lehtosalo, 1984; Miller et al., 1981; Sakiyama et al., 1984;
Sasaoka et al., 1984; Shimizu, 1982; Shimizu et al., 1982; Stone
and Kuwayama, 1985; Stone et al., 1982; Stone and McGlinn,
1988; Tervo et al., 1981, 1982a,b, 1983; Tornqvist et al., 1982; Ueda
et al., 1989). We became interested in the role of substance P in
the physiology of corneal epithelial cells, because substance P is
also a neurotrophic factor. It was ﬁrst identiﬁed in 1931 in both the
brain and small intestine of horses as a factor that lowers blood
pressure and stimulates contraction of the intestine (V. Euler and
Gaddum, 1931). It is a member of the tachkinin family of peptides
and comprises 11 amino acids (Chang et al., 1971; Kahl and Reid,
1995; Nakanishi, 1991).
Various early studies recognized that pathology at any level of
the trigeminal nerve, including the nucleus, ganglion, and nerve
ﬁbers, is associated with loss of corneal sensation and corneal
epithelial lesions (Jaffe, 1938; Magendie, 1824; Pannabecker, 1944;
Paton, 1926; Turner, 1895). Denervation of the trigeminal nerve
was also found to result in reduced mitotic activity of corneal
epithelial cells in the rabbit (Mishima,1957), and denervation of the
rabbit cornea increased epithelial permeability and retarded
epithelial wound closure (Beuerman and Schimmelpfennig, 1980).
Various types of corneal epithelial disorders including PEDs have
been found to result from insults to the trigeminal nerve and are
known collectively as neurotrophic keratopathies (Belmonte et al.,
2004a). Clinical causes of loss or impairment of trigeminal nerve
function and reduced corneal sensation include herpes simplex
virus or herpes zoster ophthalmicus virus infection (Cobo, 1988;
Holland and Schwartz, 1999; Liesegang, 1985); complications of
surgery for acoustic neurioma or trigeminal neuralgia (Blau et al.,
1969; Rosenberg et al., 1981) or of ophthalmic surgeries such as
penetrating keratoplasty, LASIK, and photorefractive keratectomy
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Campos et al., 1992; Chao et al., 2014; Chuck et al., 2000;
Ishikawa et al., 1994; Kalyvianaki et al., 2006; Kohlhaas, 1998;
Kumano et al., 2003; Lee et al., 2006; Linna et al., 2000; Mathers
et al., 1988; Matsui et al., 2001; Melki and Azar, 2001; Nassaralla
et al., 2003; Nejima et al., 2005; Rao et al., 1985; Stachs et al.,
2010; Tugal Tutkun et al., 1993; Vestergaard et al., 2013; Wilson,
2001); thermal or chemical burns of the cornea; toxic keratop-
athy such as that resulting from abuse of topical anesthetics or b-
blockers (Chen et al., 2004; Rosenwasser, 1989; Spinelli et al., 1984;
Van Buskirk, 1979; Willis and Laibson, 1970); contact lens wear;
diabetes mellitus (Cousen et al., 2007; Davidson et al., 2012a,b;
McNamara et al., 1998; Nielsen, 1978; Saito et al., 2003); aging
(Kotulak and Brungardt,1980; Roszkowska et al., 2004); some types
of corneal dystrophy such as lattice dystrophy; and congenital
diseases such as Riley-Day syndrome (Ramaesh et al., 2007). The
structure and physiology of corneal innervations (Belmonte et al.,
2004a,b; Mensher, 1974; Muller et al., 2003; Shaheen et al., 2014)
as well as neurotrophic keratopathy (Chang and Groos, 2011;
Daniele et al., 1992; Goins, 2005; Lambiase et al., 1999; Lockwood
et al., 2006; Nishida and Yanai, 2009; Okada et al., 2010; Pushker
et al., 2001; Sacchetti and Lambiase, 2014) have been extensively
reviewed elsewhere.
The possible roles of impaired corneal sensitivity and reduced
tear secretion in corneal epithelial disorders (PEDs, erosion, or SPK)
have been investigated in the clinical setting. Corneal sensitivity
was found to be signiﬁcantly reduced in patients with PEDs or
corneal erosion compared with control individuals. On the other
hand, the Schirmer test revealed that tear secretion was signiﬁ-
cantly reduced in SPK patients compared with controls (NishidaTable 2
Activity of neurotransmitters, tachykinins, and peptides derived from substance P in
synergistic promotion together with IGF-1 of rabbit corneal epithelial migration in
organ culture.
Amino acid
sequence
Synergism
with IGF-1
Neurotransmitters Substance P RPKPQQFFGLM-
amide
þ
Vasoactive
intestinal
peptide
e
CGRP e
Acetylcholine e
Norepinephrine e
Serotonin e
Tachykinins (common COOH-
terminal amino acid
sequence of FXGLM-amide)
Neurokinin A HKTDSFVGLM-
amide
e
Neurokinin B DMHDFFVGLM-
amide
e
Kassinin DVPKSDQFVGLM-
amide
e
Eledoisin pEPKSDQFIGLM-
amide
e
Physalaemin pEADPNKFYGLM-
amide
e
Peptides derived from
substance P
1e11 RPKPQQFFGLM-
amide
þ
1e7 RPKPQQF e
5e11 QQFFGLM-amide þ
6e11 QFFGLM-amide þ
7e11 FFGLM-amide þ
8e11 FGLM-amide þ
9e11 GLM-amide e
Peptides derived from COOH-
terminal sequence of
tachykinins
Substance P FGLM-amide þ
Neurokinin A, B VGLM-amide e
Kassinin VGLM-amide e
Eledoisin IGLM-amide e
Physalaemin YGLM-amide eet al., 2012). These ﬁndings suggested that a loss of corneal sensi-
tivity might contribute to the development of PEDs and corneal
erosion, whereas reduced tear secretion may be a contributing
factor for SPK. They further indicate the importance of signals
derived from corneal nerve endings for maintenance of the normal
structure and function of the cornea and for corneal wound repair.5.2.2. Role of substance P in corneal epithelial migration
The physiological relevance of corneal innervation to the
maintenance and healing of the corneal epithelium was investi-
gated by examination of the effects of the sensory neurotransmitter
substance P on epithelial migration in organ culture, on the
attachment of corneal epithelial cells to various ECM proteins, and
on corneal epithelial cell proliferation.
We found that substance P at all concentrations examined
(10e50 mg/mL) had no effect on migration of the rabbit corneal
epithelium in organ culture. Given that the cornea is regulated by
various biologically active substances in tear ﬂuid as well as by
neural factors released from corneal nerve ﬁbers, we also investi-
gated the effects of various growth factorsdincluding IGF-1, IGF-2,
insulin, EGF, basic FGF, and transforming growth factor-b (TGF-b)d
on corneal epithelial migration in the absence or presence of sub-
stance P. In the absence of substance P, only EGF among the tested
growth factors stimulated epithelial migration. In the presence of
substance P, however, epithelial migration was enhanced by EGF,
IGF-1, and IGF-2 compared with that apparent in the presence of
each growth factor alone. Insulin, basic FGF, and transforming
growth factor-b did not affect epithelial migration in the absence or
presence of substance P. This synergistic effect of EGF or IGF-1
together with substance P was found to be dependent on the
concentration of each agent (Nakamura et al., 1997a; Nishida et al.,
1996; Yamada et al., 2004).
The synergism of substance P with IGF-1 was speciﬁc in that no
other neurotransmitter examineddincluding vasoactive intestinalTable 3
Effects of eyedrops containing peptides derived from substance P (FGLM-amide) and
IGF-1 (C-domain or SSSR) on corneal epithelial wound closure in vivo.
Animal Condition Eyedrops Healing rate (% of
control)
Reference
Rabbit No treatment PBS 100 (Nakamura
et al., 1999)SP 106
FGLM 91
IGF-1 100
SP þ IGF-1 154 *
FGLM þ IGF-1 147 *
Rabbit No treatment PBS 100 (Yamada et al.,
2004)C-domain 95
IGF-1 þ FGLM 121 *
C-
domain þ FGLM
127 *
Rabbit No treatment SSSR 100 (Yamada et al.,
2006)IGF-1 þ FGLM 121 *
SSSR þ FGLM 125 *
Rat (NK
model)
No treatment PBS 100 (Nakamura
et al., 2003b)Capsaicin PBS 79 y
SP þ IGF-1 105 z
Rat (NK
model)
No treatment PBS 100 (Nagano et al.,
2003)Thermo-
coagulation
PBS 78 y
SP þ IGF-1 97 z
Rat (DM) No treatment PBS 100 (Nakamura
et al., 2003a)STZ-DM PBS 65 y
FGLM þ IGF-1 87 z
NK, neurotrophic keratopathy; DM, diabetes mellitus; STZ, streptozotocin. *Signif-
icantly increased relative to control. ySigniﬁcantly reduced relative to control.
zSigniﬁcantly increased relative to y.
Fig. 6. Molecular structure of human IGF-1. Dashed lines indicate disulﬁde bonds, and
blue wedges indicate domain boundaries.
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promoted corneal epithelial migration in the presence of IGF-1.
Furthermore, other tachkinin family membersdincluding neuro-
kinin A, neurokinin B, kassinin, eledoisin, and physalaemindhad
no effect on corneal epithelial migration in the absence or presence
of IGF-1 (Nishida et al., 1996) (Table 2).
Corneal epithelial cells attach to a greater extent to ﬁbronectin,
collagen type I, and laminin matrices than to bovine serum albu-
min as a control. Culture of HCE cells in the presence of either
substance P or IGF-1 alone had no signiﬁcant effect on the number
of cells attached to these ECM proteins. The addition of both
substance P and IGF-1, however, resulted in a marked increase in
the number of attached cells (Nishida et al., 1996). Attachment of
HCE cells to a ﬁbronectin matrix is inhibited by addition of the
GRGDSP peptide, which is derived from the cell-binding domain of
ﬁbronectin that interacts with integrin a5b1 (Kimura et al., 2007;
Nishida et al., 1988). We found that the combination of substance
P and IGF-1 increased the amount of integrin a5 mRNA, without
affecting that of integrin b1 mRNA, in HCE cells. Substance P or
IGF-1 alone had no effect on the abundance of either integrin
mRNA (Nakamura et al., 1998a). Furthermore, the combination of
substance P and IGF-1 up-regulated phosphorylation of focal
adhesion kinase (FAK) and paxillin in HCE cells (Nakamura et al.,
1998b). Together, these ﬁndings thus demonstrated that the
combination of substance P and IGF-1 up-regulates and activates
integrin a5 in corneal epithelial cells, and that it increases both the
adhesion of these cells and promotes corneal epithelial migration.
The combination of substance P and IGF-1 had no effect on the
mitotic activity of corneal epithelial cells as determined by mea-
surement of [3H]thymidine uptake (Nishida et al., 1996).
Among neurokinin receptors, NK-1 is the primary receptor for
substance P in rabbit corneal epithelial cells. The addition of an
NK-1 antagonist inhibited the synergistic effect of substance P
and IGF-1 on rabbit corneal epithelial migration in organ culture,
whereas an NK-2 antagonist was inactive, implicating NK-1 in
mediation of this action of substance P (Nakamura et al., 1997c).
Analysis of signaling downstream of NK-1 revealed that the ac-
tion of substance P was prevented by inhibitors of phospholipase
C, of the inositol 1,4,5-triphosphate receptor-mediated release of
Ca2þ from intracellular stores, and of Ca2þ- and calmodulin-
dependent protein kinase II (Yamada et al., 2005). The effect of
substance P in the synergistic action with IGF-1 on corneal
epithelial migration was thus found to be mediated by a signaling
pathway triggered by NK-1 that leads to the activation of this
protein kinase. Further studies revealed that the PKC inhibitors
calphostin C and H-7 as well as the tyrosine kinase inhibitors
genistein and herbimycin A attenuated the synergistic effect of
substance P and IGF-1 on corneal epithelial migration, impli-
cating both PKC and tyrosine kinase signaling pathways in this
effect (Ofuji et al., 2000). Finally, inhibition of p38 MAPK
signaling, but not that of ERK signaling, attenuated the stimula-
tion of corneal epithelial migration by substance P and IGF-1
(Nakamura et al., 2005).
To translate these in vitro studies to the clinic, we examined
the effect of the administration of eyedrops containing substance P
and IGF-1 on rabbit corneal epithelial resurfacing in vivo. We
removed the corneal epithelium with n-heptanol and then applied
eyedrops containing either substance P (1 mg/mL), IGF-1 (1 mg/
mL), the combination of substance P and IGF-1, or phosphate
buffered saline as a control. The healing rate of epithelial defects
was signiﬁcantly greater in eyes treated with substance P and IGF-
1 compared with those treated with substance P alone, with IGF-1
alone, or with phosphate-buffered saline, demonstrating that the
combination of substance P and IGF-1 stimulated the resurfacing
of corneal epithelial defects in healthy rabbits (Nakamura et al.,1997b) (Table 3). We further investigated the effects of eyedrops
containing substance P and IGF-1 in a rat model of neurotrophic
keratopathy induced by capsaicin. Topical application of the
combination of substance P (1 mM) and IGF-1 (1 mg/mL) in
phosphate-buffered saline improved both corneal epithelial bar-
rier function and epithelial wound healing in this animal model
(Nakamura et al., 2003b). We established another rat model of
neurotrophic keratopathydcharacterized by reduced tear secre-
tion, loss of corneal sensation, impaired epithelial barrier function,
and delayed epithelial wound healingdby thermocoagulation of
the ophthalmic branch of the trigeminal nerve. Application of
eyedrops containing substance P and IGF-1 to the denervated
cornea restored ﬂuorescein permeability of the corneal epithelium
to control levels (that is, improved barrier function) and abolished
the delay in epithelial wound healing (Nagano et al., 2003).
Together, these results thus showed that topical administration of
both substance P and IGF-1 promotes epithelial wound closure
in vivo regardless of whether the trigeminal nerve is intact or not.5.2.3. Identiﬁcation of minimum essential amino acid sequences of
substance P and IGF-1 required for synergistic promotion of corneal
epithelial migration
Substance P is a constituent of sensory nerve ﬁbers and has been
postulated to mediate various physiological functions including
vasodilation and inﬂammation (Payan, 1989; Pernow, 1983). How-
ever, it is readily degraded and inactivated by neuropeptidases such
as carboxypeptidases and endopeptidases (Guyon et al., 1979;
Matsas et al., 1983, 1984). The identiﬁcation of smaller and more
stable peptides that retain biological activity would thus be ex-
pected to facilitate the clinical development of substance P.
IGF was originally known by various names based on its activ-
ities, such as sulfation factor (and later, somatomedin C)
(Daughaday et al., 1972; Salmon and Daughaday, 1957), non-
suppressible insulin-like activity (Froesch et al., 1963), and
multiplication-stimulating activity (Pierson and Temin, 1972). The
term insulin-like growth factor was proposed in 1976
(Rinderknecht and Humbel, 1976). As this historical overview
shows, IGF isoforms have a wide variety of physiological functions
in the body (Daughaday and Rotwein, 1989; LeRoith et al., 1991).
They thus contribute to regulation of the proliferation, differenti-
ation, survival or apoptosis (Kooijman, 2006), migration (Jones
et al., 1995), or adhesion (Mauro et al., 2003) of most cell types,
as well as play important roles in metabolism (Clemmons, 2012),
Table 4
Comparison of the amino acid sequences of human proinsulin, IGF-1, and IGF-2.Common sequences are shown in bold and underlined.
B domain
Proinsulin FVNQHLCGSHLVEALYLVCGERGFFYTPKT
IGF-1 GPETLCGAELVDALQFVCGDRGFYFNKPT
IGF-2 AYRPSETLCGGELVDTLQFVCGDRGFYFSRPA
C domain
Proinsulin RREAEDLQVGQVELCGGGPGAGSLQPLALEGSLQKR
IGF-1 GYGSSSRRAPQT——————————————————————
IGF-2 –SRVSRRSR————————————————————————
A domain D domain
Proinsulin GIVEQCCTSICSLYQLENYCN——————
IGF-1 GIVDECCFRSCDLRRLEMYCAPLKPAKSA
IGF-2 GIVEECCFRSCDLALLEYYCAT–PAKSE
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(Al-Kharobi et al., 2014). Clinical application of IGF-1 might there-
fore be expected to be associated with undesirable side effects.
Identiﬁcation of the minimum essential amino acid sequence of
IGF-1 for a particular desired effect might minimize the likelihood
of the development of such adverse effects.
We therefore adopted a similar strategy to delineate partial
amino acid sequences of substance P and IGF-1 responsible for the
synergistic stimulation of corneal epithelial migration.Fig. 7. Sensitization of corneal epithelial migration to the stimulatory effect of the C-
domain peptide of IGF-1 by FGLM-amide. The length of the path of epithelial migration
was measured for the rabbit cornea in organ culture in the presence of the indicated
concentrations of the C-domain peptide of IGF-1 and in the absence or presence of the
substance P-derived peptide FGLM-amide (20 mM).
Modiﬁed with permission from Yamada et al. (2005).5.2.3.1. FGLM-amide: a peptide derived from substance P.
Substance P comprises the 11-amino acid sequence Arge-
ProeLyseProeGlneGlnePheePheeGlyeLeueMeteamide. The
ability of short peptides derived from the carboxyl terminus of
substance P to reproduce the vasodilator, spasmogenic, and veno-
constrictor activities of the full-length molecule were investigated.
The carboxyl-terminal tripeptide (GLM-amide) and tetrapeptide
(FGLM-amide) were found to possess weak vasodilator activity, the
pentapeptide (FFGLM-amide) to exert substantial spasmogenic and
vasoactive effects, and peptides with six or more amino acids to
possess activities identical to the intact molecule (Bury and
Mashford, 1976). We similarly set out to identify the minimum
amino acid sequence of substance P necessary for the synergistic
effect with IGF-1 on corneal epithelial migration (Nakamura et al.,
1997a).
We found that a peptide containing the seven amino acids at the
amino terminus of substance P did not affect epithelial migration in
the absence or presence of IGF-1 in the rabbit corneal organ culture
system (Table 2). In contrast, peptides comprising residues 5e11,
6e11, 7e11, and 8e11 showed synergy with IGF-1 in the promotion
of corneal epithelial migration, whereas the tripeptide derived
from the carboxyl terminus did not. These results thus identiﬁed
the four-amino acid sequence FGLM-amide at the carboxyl termi-
nus of substance P as the minimum essential sequence for syner-
gism with IGF-1.
Tachykinins share the characteristic amino acid sequence
PheeXeGlyeLeueMeteamide at the carboxyl terminus, with this
portion of themolecular structure of tachykinins being essential for
many of their biological activities (Severini et al., 2002). Neurokinin
A and B as well as kassinin thus contain the sequence VGLM-amide
at the carboxyl terminus, whereas eledoisin contains IGLM-amide
and physalaemin contains YGLM-amide. In contrast to the FGLM-
amide peptide derived from substance P, peptides corresponding
to these various four-amino acid sequences did not show a syner-
gistic effect with IGF-1 on corneal epithelial migration (Table 2)
(Nakamura et al., 1999).
We also found that, like the combination of substance P and IGF-
1, the combination of FGLM-amide and IGF-1 signiﬁcantlyincreased the attachment of HCE cells to a ﬁbronectin matrix and
up-regulated the abundance of integrin a5 mRNA in these cells
(Chikama et al., 1999). Furthermore, the administration of eyedrops
containing FGLM-amide and IGF-1 accelerated corneal epithelial
wound closure in rabbits as well as did those containing substance
P and IGF-1 (Nakamura et al., 1999). In rats with streptozotocin-
induced diabetes, in which epithelial wound closure is delayed,
the administration of eyedrops containing FGLM-amide plus IGF-1
facilitated corneal epithelial wound healing, suggesting that such
treatment might prove effective in humans with diabetic keratop-
athy (Nakamura et al., 2003a) (Table 3).
Substance P induces miosis, or a decrease in pupil size (Soloway
et al., 1981). We found that instillation of substance P signiﬁcantly
reduced pupil size in rabbits whether or not IGF-1 was present.
However, FGLM-amide with or without IGF-1 did not affect pupil
size (Nakamura et al., 1999), indicating that this partial amino acid
sequence of substance P retains the desired biological activity of
synergistic promotion with IGF-1 of corneal epithelial migration,
but that it lacks the undesired miotic effect. On the basis of these
results, we concluded that a peptide corresponding to the four-
amino acid sequence at the carboxyl terminus of substance P
(FGLM-amide) was a feasible substitute for the full-lengthmolecule
for clinical use.
5.2.3.2. SSSR: a peptide derived from IGF-1. Members of the insulin
family of proteins, including insulin, IGF-1, and IGF-2, have highly
similar amino acid sequences (~50% identity) and molecular
Fig. 8. Eyedrops containing FGLM-amide and SSSR peptides for the treatment of corneal PEDs. Photographs (upper panels) and slitlamp microscopic images of ﬂuorescein staining
(lower panels) for a patient with PEDs both before (left panels) as well as 1 (center panels) and 6 (right panels) weeks after the initiation of treatment with eyedrops containing
FGLM-amide and SSSR.
Reproduced with permission from Yamada et al. (2008).
Fig. 9. Schematic representation of the pathobiology of corneal PEDs and of both the
provision of matrix proteins and activation of epithelial cells as fundamental concepts
for the development of new drugs.
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with a molecular size of 7649 Da (Rinderknecht and Humbel, 1978)
(Fig. 6). A key difference between the molecular structure of insulin
and those of IGF-1 and IGF-2 is the presence of a D domain in the
latter proteins. In addition, although proinsulin, like IGF-1 and IGF-
2, possesses a C domain, this region is removed during the pro-
cessing of proinsulin to insulin, resulting in the double-chain
structure of insulin (Table 4).
We found that both IGF-1 and IGF-2 exhibit a synergistic effect
together with substance P or the substance P-derived peptide
FGLM-amide on corneal epithelial migration in the organ culture
system for the rabbit cornea, whereas insulin was inactive in this
regard. Furthermore, a 12-amino acid peptide corresponding to the
C domain of IGF-1 (Gly30eThr41) mimicked this effect of full-length
IGF-1 in the presence of FGLM-amide, whereas the C peptide of
proinsulin or the D domain of IGF-1 did not. Eyedrops containing
FGLM-amide and either intact IGF-1 or a peptide corresponding to
the C domain of IGF-1 were also found to promote epithelial wound
closure in rabbits, whereas the C domain alone was inactive
(Yamada et al., 2004).
To delineate further the essential amino acid sequence of IGF-1,
we tested shorter peptides corresponding to the C domain for their
effects on corneal epithelial migration. The Gly32ePro39 peptide
showed a synergistic effect with FGLM-amide identical to that of
Gly30eThr41. We then replaced individual amino acids between
Gly32 and Arg37 with Ala in a glutathione S-transferase fusion
protein and examined the effects of each protein on epithelial
migration. Replacement of Ser33, Ser34, Ser35, or Arg36 with Ala
resulted in loss of the synergistic effect with FGLM-amide, whereas
replacement of Gly32 or Arg37 had no effect on synergism. We
therefore concluded that the four-amino acid sequence SSSR is
necessary and sufﬁcient for the synergistic action of IGF-1 with
substance P on corneal epithelial migration. Changes to the order of
these four amino acids also resulted in a loss of synergy, indicating
the importance of the precise SSSR sequence. The combination of
FGLM-amide and SSSR peptides was found to be effective for the
promotion of epithelial wound closure in vivo. Furthermore,
whereas IGF-1 induces the formation of prominent new vessels
when injected into the corneal stroma, topical application of the
SSSR peptide did not result in such an effect. Shortening of the full-
length IGF-1 molecule to just the tetrapeptide SSSR thus retains the
synergistic effect with substance P on corneal epithelial wound
healing but results in a loss of angiogenic activity (Yamada et al.,
2006).
Fig. 10. Strategy for new drug development as exempliﬁed by the development of peptides for the treatment of corneal PEDs.
T. Nishida et al. / Progress in Retinal and Eye Research 47 (2015) 38e63 55Our data further revealed that substance P or the substance P-
derived peptide FGLM-amide sensitizes epithelial cells to the in-
duction of migration by IGF-1 or the C-domain peptide, shifting the
concentrationeresponse curve for IGF-1 or the C-domain peptide
to the left (Yamada et al., 2005) (Fig. 7). A stimulatory effect of IGF-1
alone on corneal epithelial migration was thus apparent at
unphysiologically high concentrations (1 mM) of the growth fac-
tor, which are about four orders of magnitude greater than those
found to be effective in the presence of substance P. This sensitizing
effect of substance P was also apparent with the induction of
corneal epithelial migration by other biological agents including
ﬁbronectin and IL-6 (Yamada et al., 2005).
The action of the C-domain peptide of IGF-1 or the SSSR tetra-
peptide in the synergistic promotion of corneal epithelial migration
was found not to be mediated by the IGF-1 receptor, given that
these peptides failed to induce phosphorylation of Akt, a down-
stream effect of IGF-1 receptor activation in HCE cells (Yamada
et al., 2004). Moreover, a mutant form of IGF-1 in which Ser34 is
replaced by Ala does not manifest a synergistic effect with sub-
stance P on corneal epithelial migration even though it retains the
ability to activate the IGF-1 receptor. Clinical application of the SSSR
peptidewould thus be expected to be free of potentially deleterious
side effects associated with treatment with full-length IGF-1.
5.3. Clinical application of substance P plus IGF-1 or of derived
peptides for treatment of corneal PEDs
The ﬁrst patient treated with eyedrops containing substance P
and IGF-1 was a 16-month-old girl with severe neurotrophic and
anhidrotic keratopathy who had central epithelial defects (5 by
5mm) in both eyes. Despite intensive lubrication and application of
bandage contact lenses, rapid stromal melting occurred bilaterally,leading to the development of a central descemetocele in the right
eye. In an attempt to save the remaining left eye, eyedrops con-
taining substance P (250 mg/mL) in balanced salt solution were
administered, but no improvement was apparent after 10 days.
Insulin (3 mg/mL) was then added to the substance P eyedrops,
again without any improvement. The treatment was then changed
to eyedrops containing substance P (250 mg/mL) and IGF-1 (25 ng/
mL). The lesion in the left eye began to undergo visible epithelial-
ization within 5 days, and complete epithelialization was achieved
after 30 days. Three months later, the corneal epithelium remained
intact and the central stroma was less opaque (Brown et al., 1997).
These clinical ﬁndings were thus identical to those previously ob-
tained in vitro; that is, only the combination of substance P and IGF-
1 promoted corneal epithelial migration, with substance P either by
itself or in combination with insulin being inactive.
Given that our preclinical studies showed that the substance P-
derived peptide FGLM-amide mimics the parent molecule, we also
administered eyedrops containing FGLM-amide and IGF-1 to a 55-
year-old woman with large corneal PEDs in her left eye associated
with neurotrophic keratopathy due to trigeminal nerve palsy. Her
visual acuity was 2/100 with stromal edema. Two days after the
initiation of treatment with eyedrops containing both FGLM-
amide (1 mg/mL) and IGF-1 (1 mg/mL) four times a day, visible
epithelial resurfacing had begun. After 1 week, the epithelial de-
fects were <10% of their original size, and complete epithelial
resurfacing was achieved within 2 weeks. The stromal edema
started to subside thereafter, with corneal transparency being
achieved after 4 weeks. The patient's visual acuity returned to 20/
50 (Chikama et al., 1998).
The clinical efﬁcacy of eyedrops containing FGLM-amide and
IGF-1 for the treatment of PEDs in individuals with neurotrophic
keratopathy was examined in a prospective open study. Eleven
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opathy were treated for up to 28 days by the administration of
eyedrops containing FGLM-amide (1 mg/mL) and IGF-1 (1 mg/mL).
Complete epithelial resurfacing was achieved in eight of the nine
(89%) cases that showed a response. The defects were completely
resurfaced in two of the nine (22%) and ﬁve of the nine (56%) cases
within 1 and 2 weeks, respectively, after treatment initiation. No
adverse effects were observed in any of the 11 patients. This trial
thus showed that eyedrops containing FGLM-amide and IGF-1
induced the rapid resurfacing of PEDs in individuals with neuro-
trophic keratopathy (Nishida et al., 2007).
Our ﬁnding that the tetrapeptide SSSR derived from the C
domain of IGF-1 mimics the intact molecule prompted us to un-
dertake a prospective open study of the clinical efﬁcacy of eyedrops
containing FGLM-amide (1 mg/mL) and SSSR-triﬂuoroacetate
(0.05629 mg/mL) in phosphate-buffered saline for the treatment
of PEDs in individuals with neurotrophic keratopathy. Twenty-ﬁve
consecutive patients (26 eyes) were enrolled in the study. The
epithelial defects resurfaced completely in 19 of the 26 eyes (73%)
within 4 weeks after treatment initiation. Complete resurfacing of
the defects was apparent in 18 of 22 (82%) or in one of four (25%)
eyes without or with limbal stem cell deﬁciency, respectively. No
adverse effects of treatment were observed in any of the subjects.
Eyedrops containing FGLM-amide and SSSR were thus shown to
induce the rapid resurfacing of PEDs in stem cell-positive in-
dividuals with neurotrophic keratopathy (Yamada et al., 2008). A
representative case is shown in Fig. 8.
The efﬁcacy of eyedrops containing peptides based on substance
P (FGLM-amide) and IGF-1 (SSSR) for prevention of SPK after
cataract surgery in individuals with type 2 diabetes was also
examined. Twenty-nine patients (29 eyes) with diabetes were
enrolled in a double-masked, prospective, randomized, placebo-
controlled clinical study. They were randomly assigned to one of
two groups that received eyedrops containing either FGLM-amide
and SSSR (n ¼ 14) or phosphate-buffered saline (n ¼ 15) four
times a day for 14 days beginning 1 day after phacoemulsiﬁcation.
SPK scores (area, density, and combined area and density) were
determined (Miyata et al., 2003). SPK scores did not differ between
the two groups before surgery or before initiation of treatment. At
day 2 after treatment initiation, all SPK scores were signiﬁcantly
lower in the FGLM-amide-SSSR group than in the control group.
The density score was also signiﬁcantly lower in the former group
at day 7 after surgery. All scores returned to preoperative levels by
day 14 after surgery in both groups. Our study thus showed that
eyedrops containing FGLM-amide and SSSR are effective for the
prevention of SPK after cataract surgery in diabetic patients
(Chikamoto et al., 2009).
6. Development of new peptide drugs for the treatment of
PEDs of the cornea
Among the various types of corneal epithelial disorders, PEDs
remain the most difﬁcult to treat, with the persistence of these
defects being a manifestation of underlying disease. Furthermore,
loss of the corneal epithelium may result in the activation of ker-
atocytes in the corneal stroma and lead to the development of ul-
ceration and perforation. It is thus essential to restore the
continuity of the epithelium and to protect corneal structure and
function from further degradation in order to save the vision of
affected individuals. Currently available therapeutic approaches are
largely based on protection of the ocular surface by lubrication,
contact lens wear, tarsorrhaphy, or viscous solution application.
Progress in cell and molecular biology over the last several decades
now allows us to discuss the underlying mechanisms of PEDs in
terms of the cells and molecules involved, withﬁbronectineintegrin interactions having been found to play a
central role in corneal epithelial wound healing.
Corneal PEDs are characterized by a loss of epithelial cell
adhesion to the underlying matrix, by excessive degradation of
matrix proteins associated with inﬂammation, and by the inability
of epithelial cells to initiate migration. On the basis of these char-
acteristics, two types of new therapeutic approach can be consid-
ered: the provision of an appropriate substrate to serve as a
provisional matrix for the attachment and migration of epithelial
cells, and the activation of epithelial cells to up-regulate integrin
receptors for ECM proteins (Fig. 9).
In this review, we have discussed ﬁbronectin as a candidate
exogenous substrate to promote the attachment and migration of
corneal epithelial cells. Whereas corneal epithelial cells are able to
attach to basement membrane proteins including ﬁbronectin,
laminin, and collagen types I and IV, ﬁbronectin is the most effec-
tive of these proteins for stimulating cell motility. To overcome the
practical problems associated with the production of ﬁbronectin
eyedrops, we have developed a peptide corresponding to the sec-
ond cell-binding site of ﬁbronectin and shown it to be effective in
facilitating the migration of corneal epithelial cells. The early clin-
ical results obtained with such PHSRN eyedrops for the treatment
of PEDs are encouraging, but double-masked, multicenter clinical
trials are required to establish them for use in the clinic.
We have also shown that eyedrops containing the combination
of substance P and IGF-1 are effective for the treatment of corneal
PEDs. Furthermore, by identifying the minimum amino acid
sequence required for this activity of both substance P and IGF-1,
we have developed eyedrops containing the combination of two
peptides, FGLM-amide from substance P and SSSR from IGF-1. The
clinical use of peptides instead of the intact parent molecules has
several advantages, including the potential elimination of un-
wanted side effects. Furthermore, small peptides are more stable
than full-length proteins and are less expensive to produce.
Two organizations, academia and industry, play key comple-
mentary roles in drug development, as exempliﬁed by our strategy
for the development of peptide drugs for the treatment of non-
healing corneal epithelial defects (Fig. 10). Most clinical trials con-
ducted at academic institutions are open studies of treatment
modalities, whereas pharmaceutical companies are better equip-
ped to perform the large-scale, well-controlled, double-masked
trials required for drug approval because of the large ﬁnancial
and manpower resources that are needed for these studies.
Ophthalmologists often experience cases for which the
currently available prescription drugs or surgical maneuvers do not
effectively cure the patient. Whether the number of such patients is
small or large, they reveal an unmet need for new treatments.
Intensive observation of these patients may shed light on the un-
derlying pathological mechanism that gives rise to the untreatable
condition as well as suggest targets for new drug development.
Such proposed mechanisms and targets can then be evaluated by
scientists in the laboratory, with such evaluation including
screening for potential therapeutic agents with the use of in vitro
systems such as cell or organ culture. Identiﬁcation of such candi-
date agents in in vitro systems can then be followed by examination
of their effectiveness in animal models. Remaining agents are then
returned to ophthalmologists for the performance (with Institu-
tional Review Board approval) of clinical studies (mostly, open
studies) to determine whether they are indeed effective for treat-
ment of the disease or condition in the clinical setting.
Ophthalmologists and scientists in academia may attempt to
modify the original drug to obtain one with a simpler chemical
structure, greater speciﬁc activity, or fewer adverse effects, at
which point further drug development is usually undertaken by
industry. Industry thus performs additional preclinical studies, a
T. Nishida et al. / Progress in Retinal and Eye Research 47 (2015) 38e63 57phase I trial for evaluation of drug safety in normal human volun-
teers, phase IIa and phase IIb trials for determination of the correct
dose and evaluation of clinical efﬁcacy as well as safety, and, ﬁnally,
a multicenter, double-masked phase III trial. If the results of the
various trials are satisfactory, the drug is submitted for approval by
the relevant governmental health authority. The major concern of
industry is clinical efﬁcacy of the drug in a large number of patients
as well as its marketability and proﬁtability, and the company may
abandon development of a new drug at any stage depending on the
anticipated amount of time and money required to bring it to
market.
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